

1
2 **ARF1 prevents aberrant type I IFN induction by regulating STING**
3 **activation and recycling**

4
5 Maximilian Hirschenberger¹, Alice Lepelley², Ulrich Rupp³, Susanne Klute¹, Victoria
6 Hunszinger¹, Lennart Koepke¹, Veronika Merold⁴, Blaise Didry-Barca², Fanny Wondany⁶, Tim
7 Bergner³, Sebastian Wiese⁷, Stefano Volpi^{8,9}, Marco Gattorno⁸, Riccardo Papa⁸, Sally-Ann
8 Lynch^{10,11}, Marte G. Haug¹², Gunnar Houge¹³, Kristen M. Wigby^{14,15}, Jessica Sprague¹⁶, Jerica
9 Lenberg¹⁵, Clarissa Read³, Paul Walther³, Jens Michaelis⁶, Frank Kirchhoff¹, Carina C. de Oliveira
10 Mann⁴, Yanick J. Crow^{2,5,*}, Konstantin M.J. Sparrer^{1,*}

11
12 ¹Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany
13 ²Université Paris Cité, *Imagine* Institute, Laboratory of Neurogenetics and Neuroinflammation,
14 INSERM UMR1163, F-75015, Paris, France
15 ³Central Facility for Electron Microscopy, Ulm University, 89081 Ulm, Germany
16 ⁴Institute of Virology, Technical University of Munich, 81675 Munich, Germany
17 ⁵MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh,
18 Edinburgh, United Kingdom
19 ⁶Institute of Biophysics, Ulm University, 89081 Ulm, Germany
20 ⁷Core Unit Mass Spectrometry and Proteomics, Ulm University Medical Center, 89081 Ulm,
21 Germany
22 ⁸Centro per le Malattie Autoinfiammatorie e Immunodeficienze, IRCCS Istituto Giannina Gaslini,
23 Genoa, Italy
24 ⁹Università degli Studi di Genova, Genoa, Italy
25 ¹⁰Children's Health Ireland, Crumlin, Dublin, Eire
26 ¹¹University College Dublin, Dublin, Eire
27 ¹²Department of Medical Genetics, St. Olav's Hospital, Trondheim, Norway
28 ¹³Department of Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway
29 ¹⁴Department of Pediatrics, Division of Genetics, University of California, San Diego, California,
30 USA
31 ¹⁵Rady Children's Institute for Genomic Medicine, San Diego, California, USA
32 ¹⁶Division of Pediatric and Adolescent Dermatology, University of California, San Diego,
33 California; Rady Children's Hospital, San Diego

34
35 *Address correspondence to: Yanick J. Crow: yanickcrow@mac.com; Konstantin M.J. Sparrer:
36 Konstantin.Sparrer@uni-ulm.de.

37
38 **RUNNING TITLE:** ARF1 regulates STING activation and trafficking

39 **KEYWORDS:** ARF1, Interferon, STING, cGAS, Interferonopathy

40 **ABSTRACT**

41 Type I interferon (IFN) signalling is tightly controlled. Upon recognition of DNA by cyclic GMP-
42 AMP synthase (cGAS), stimulator of interferon genes (STING) translocates along the endoplasmic
43 reticulum (ER)-Golgi axis to induce IFN signalling. Termination is achieved through autophagic
44 degradation or recycling of STING by retrograde Golgi-to-ER transport. Here, we identify the
45 GTPase ARF1 as a crucial negative regulator of cGAS-STING signaling. Heterozygous ARF1
46 missense mutations cause a novel type I interferonopathy associated with enhanced IFN stimulated
47 gene expression. Disease-associated, GTPase-defective, ARF1 results in increased cGAS-STING
48 dependent type I IFN signalling in cell lines and primary patient cells. Mechanistically, mutated
49 ARF1 perturbs mitochondrial fusion causing cGAS activation by aberrant mitochondrial DNA,
50 and promotes accumulation of active STING at the Golgi/ERGIC due to defective retrograde
51 transport. Our data show that ARF1 has an unexpected dual role in maintaining cGAS-STING
52 homeostasis, through the promotion of mitochondrial fusion and STING recycling.

53 INTRODUCTION

54 Type I interferon (IFN) mediated innate immunity constitutes an essential element in the response
55 to viral infection, establishing an anti-viral state through the upregulation of hundreds of IFN
56 stimulated genes (ISGs)¹⁻³. Contrasting with this protective role against viral infection,
57 inappropriate activation of an IFN response is pathogenic, eventually leading to tissue damage⁴.
58 This dichotomy is particularly well illustrated by the type I interferonopathies, Mendelian diseases
59 characterised by chronically enhanced type I IFN signaling^{4,5}. Clinically, these disorders often
60 manifest with neurological features such as encephalopathy, cerebral calcification, leukodystrophy
61 and cerebral atrophy. In addition, extra-neurological involvement can also be seen, with chilblain-
62 like skin lesions a particularly frequent association. Notably, the study of the pathological basis of
63 the type I interferonopathies has provided molecular insight into the induction and regulation of
64 type I IFN signalling in human health and disease⁴.

65 Type I IFNs can be induced through the sensing of foreign viral nucleic acids by innate immune
66 receptors, among them cyclic GMP-AMP synthase (cGAS)^{2,6-8}. Notably, cGAS can also be
67 triggered by self-DNA that is erroneously present in the cytoplasm⁹. Upon binding to cytoplasmic
68 DNA, cGAS catalyses the production of a second messenger 2'-3' cyclic guanosine
69 monophosphate-adenosine monophosphate (cGAMP) from GTP and ATP^{6,10}. cGAMP in turn
70 binds to the signalling adaptor stimulator of IFN genes (STING), residing in its inactive form at
71 the endoplasmic reticulum (ER), causing STING to change conformation, oligomerise, and
72 accumulate in the Golgi⁷. Trafficking via the ER-Golgi axis is a major determinant of both STING
73 activation and signal termination¹¹⁻¹³. Activated STING is transported from the ER to the ER-
74 Golgi intermediate compartment (ERGIC)/Golgi via coatamer protein complex II (COPII)
75 vesicles. At the Golgi/ERGIC, STING recruits Tank binding kinase 1 (TBK1), which in turn
76 activates the transcription factors IRF3 and NF- κ B. Both transcription factors eventually

77 translocate into the nucleus, leading to the induction of type I IFN and other (pro-)inflammatory
78 cytokines. The current model proposes that, after TBK1 activation, STING is transported to the
79 trans-Golgi network (TGN)/Golgi-associated vesicles where it is degraded via the autophagic-
80 lysosomal pathway for signal termination¹³. In addition, increasing evidence suggests that STING
81 can be recycled back to the ER¹⁴⁻¹⁷. Upon recruitment by Surfeit 4 (SURF4) to coatomer protein
82 complex I (COPI) vesicles, STING is transported in a retrograde manner from the Golgi/ERGIC
83 to the ER, thus also contributing to signal termination¹⁵⁻¹⁷. COPI trafficking is a highly conserved
84 pathway down to yeast, functioning through the combined action of seven coatomer subunits: α -
85 COP, β -COP, β' -COP, γ -COP, δ -COP, ε -COP, and ζ -COP. Despite these insights, the precise
86 mechanism(s) and key players involved in STING flux and signal termination remain incompletely
87 understood.

88 Small GTPases are important mediators of intracellular trafficking, among them the family of
89 ADP-ribosylation factors (ARFs) comprising five highly homologous members in humans (ARF1,
90 ARF2/4, ARF3, ARF5 and ARF6)¹⁸. These molecules have distinct but overlapping roles generally
91 defined by their subcellular localisation¹⁹. For example, ARF1 is predominantly localised to the
92 cis-Golgi, trans-Golgi and ERGIC²⁰, whereas ARF6 is present at the plasma membrane²¹. Their
93 major function is to recruit coat proteins, such as COPI components, and mediate budding of
94 transport vesicles from ER/Golgi surfaces. GTPase activity is required for vesicle formation and
95 cargo recruitment by ARF proteins, cycling between a membrane-associated GTP-bound state and
96 a GDP-bound cytoplasmic state²². GTPase activity, and GDP to GTP exchange, are regulated by
97 a distinct set of GTPase accelerating proteins (GAP) and guanine nucleotide exchange factors
98 (GEF), respectively, thereby in turn controlling the activity of ARF proteins²².

99 Through the characterisation of a novel type I interferonopathy, we have discovered that the small
100 GTPase ARF1 plays a key role in regulating cGAS-STING activity. ARF1 prevents aberrant type

101 I IFN induction and signalling via a dual mechanism. First, functional ARF1 is required for proper
102 mitochondrial fusion, thus preventing the release and sensing of mitochondrial DNA (mtDNA). In
103 addition, ARF1 mediates retrograde transport of activated STING from the ERGIC/Golgi for
104 signal termination. Mutation of the R99 residue in ARF1 is associated with a type I
105 interferonopathy state, demonstrating attenuated GTPase activity and impaired function.
106 Consequently, mtDNA leaks into the cytoplasm where it triggers cGAS. In addition, signal
107 termination via ER-Golgi trafficking is defective, leading to elevated ISG expression. Our results
108 reveal previously unappreciated roles for ARF1 in cGAS-STING activation and signal termination
109 essential to the maintenance of cellular homeostasis, and provide a mechanistic explanation for a
110 novel auto-inflammatory disease.

111 **RESULTS**

112 **Mutations in ARF1 define a novel type I interferonopathy**

113 As part of an ongoing protocol involving the agnostic screening of patients with uncharacterized
114 phenotypes for an upregulation of type I IFN signalling, we identified a patient with skin lesions
115 and significant developmental delay to harbour a *de novo* c.295C>T / p.(R99C) substitution in
116 ARF1 (Supplementary information). His skin disease was consistent with a diagnosis of chilblain
117 lupus, a clinical sign frequently observed in a number of type I interferonopathies including
118 Aicardi-Goutières syndrome (AGS) and STING associated vasculopathy of infancy (SAVI) (Fig.
119 1a-c). Through Decipher and GeneMatcher/Matchmaker exchange²³, we ascertained two
120 additional patients (RH2003, KW2022) with the same p.(R99C) substitution, in one of whom we
121 could demonstrate that the variant arose *de novo*. Both of these patients exhibited similar skin
122 lesions (Fig. 1d–g), in association with significant developmental delay. We then identified a

123 further patient with a *de novo* c.296G>A / p.(R99H) substitution and a history of cold hands and
124 feet, without frank chilblains (Supplementary information).

125 ARF1 is a small GTPase with a myristylation anchor at the N-terminus that mediates membrane
126 association^{22,24}. This is followed by an amphipathic helix and the GTPase domain, consisting of
127 two Switch domains (SW1 and 2) (Fig. 1h). Overall, ARF1 is highly constrained (pLi = 0.9). The
128 arginine at position 99 is conserved from yeast to humans (Fig. 1i and Extended Data Fig. 1a),
129 there are no variants at this residue on gnomAD, and a substitution for a cysteine or histidine is
130 predicted as damaging by *in silico* analyses (Supplementary table 1). Where tested, all (7 of 8)
131 parents were found to be wild type (WT) on both alleles of ARF1 (Extended Data Fig. 1b). Of
132 note, the p.(R99H) substitution was previously reported as a *de novo* mutation in a child with
133 developmental delay and periventricular nodular heterotopia²⁵. In Patient 1, we observed increased
134 ISG expression in peripheral blood on the two occasions assayed, and in Patient 2 on the one
135 occasion (Fig. 1j and Supplementary information). IFN signalling status could not be assessed in
136 two other patients.

137 Taken together, these data indicated that mutation of the arginine at position 99 in ARF1 underlays
138 a novel human type I interferonopathy.

139 **ARF1 R99C induces STING-dependent type I IFN activation**

140 To understand the molecular basis of enhanced type I IFN signalling in the context of this novel
141 human type I interferonopathy, we examined the impact of ARF1 R99C expression on innate
142 immune activation. The activity of ARF1 R99C was compared with ARF1 Q71L, which locks the
143 protein in its GTP-bound state, and T31N which is trapped in the GDP-bound state²⁶. In HEK293
144 cells stably expressing STING (293-Dual-hSTING-R232), transient expression of ARF1 R99C
145 was sufficient to induce type I IFN signalling in a dose-dependent manner, as assessed by IFN

146 stimulated response element (ISRE) reporter activity (Fig. 2a, b and Extended Data Fig. 2a). ARF1
147 Q71L also induced ISRE promoter activity, albeit less robustly than R99C, while ARF1 T31N had
148 only a minor effect. STING was required for induction of type I IFN signalling by ARF1 R99C in
149 HEK293T cells (Fig. 2c and Extended Data Fig. 2b). To avoid triggering high background cGAS-
150 STING dependent responses by plasmid transfection, we then used a lentiviral transduction
151 strategy. Lentivirus-mediated expression of ARF1 R99C in A549-ISRE reporter cells, that
152 naturally express STING and cGAS, resulted in activation of type I IFN signalling (Fig. 2d). These
153 data suggest that endogenous cGAS-STING proteins are sufficient for signalling induction.
154 Expression of WT ARF1 had no effect, compared to treatment with IFN- β and cGAMP used as
155 positive controls. Besides inducing type I IFN via IRF3, cGAS-STING signalling also enhances
156 NF-kB activity²⁷. In line with this, expression of ARF1 R99C in A549 cells induced NF-kB
157 signalling (Fig. 2e), whereas expression of ARF1 WT had no effect. Activity of the kinase TBK1
158 is required downstream of cGAS-STING to activate NF-kB and IRF3²⁸. As expected,
159 overexpression of either R99C or Q71L ARF1 in HEK293T cells ectopically expressing cGAS
160 and STING significantly increased the amount of active (i.e. phosphorylated) TBK1 (Fig. 2f, g).
161 Of note, decreased amount of endogenous STING protein upon co-transfection with ARF1 R99C
162 is consistent with STING activation leading to degradation, as observed for STING activation by
163 cGAMP stimulation (Fig. 2e)¹³.

164 To assess these observations in a more physiological setting, we performed experiments using
165 primary human fibroblasts derived from healthy individuals, and from an ARF1-mutated patient.
166 First, primary human lung cells from healthy donors were complemented with ARF1 WT and
167 ARF1 R99C by lentiviral transduction. Only the expression of ARF1 R99C, and exposure to the
168 positive controls cGAMP and IFN- β , resulted in upregulation of ISG mRNAs (OAS1, Mx1) in
169 primary human lung fibroblasts (Fig. 2h, Extended Data Fig. 2c). To determine whether patient-

170 derived primary fibroblasts release type I IFN, we transferred supernatant from fibroblast cultures
171 of healthy donors (n1 and f1, genotype ARF1 WT) and one patient (#Patient 1, heterozygous ARF1
172 R99C) on to type I IFN signalling reporter HEK293T cells. Only supernatants from the patient-
173 derived cells resulted in a significant induction of the reporter (Fig. 2i).

174 Taken together, these results indicate that expression of ARF1 R99C induces a STING-dependent
175 type I IFN response in cell line models and patient-derived primary cells.

176 **Mitochondrial DNA released in the presence of ARF1 R99C triggers cGAS activity**

177 Since the induction of type I IFN signalling by ARF1 R99C was dependent on STING (Fig. 2c),
178 we wondered whether and how cGAS may be involved. Inhibition of cGAS activity using a
179 pharmacological inhibitor, G140, significantly reduced ISRE promoter activation by ARF1 R99C
180 in 293-Dual-hSTING-R232 cells (Extended data Fig. 3a). In line with this, expression of ARF1
181 WT and R99C via lentiviral transduction in WT and cGAS KO THP-1 monocytes revealed that
182 IFN signalling was only induced in the presence of cGAS (Fig. 3a). As expected, IFN signalling
183 upon stimulation with IFN- β and cGAMP was barely affected. These results suggest that cGAS
184 facilitates type I IFN signalling induced by ARF1 R99C. ARF1 has been reported to regulate
185 mitochondrial homeostasis^{29,30}. Thus, we examined whether mutation at R99 may disrupt this
186 function, promoting release of mtDNA, which in turn might activate cGAS^{31,32}. Electron
187 microscopy of HEK293T cells revealed mitochondrial disruption in the presence of ARF1 R99C,
188 but not WT ARF1 (Fig. 3b). Indicative of mitochondrial damage, small electron-dense granules
189 were observed in the mitochondria of R99C-expressing cells (Fig. 3b, left panel). With increasing
190 mitochondrial degeneration these granules became larger, and the intermembrane space of the
191 cristae more inflated (Fig. 3b, middle and right panel). To determine the presence of mtDNA in
192 the cytoplasm, we performed fractionation of cells into nuclear, cytoplasmic and mitochondrial

193 fractions (Fig. 3c). We detected higher levels of mtDNA in the cytoplasm upon overexpression of
194 ARF1 R99C and Q71L compared to WT ARF1 (Fig. 3d). Treatment with ABT-737 and Q-VD-
195 OPH (ABT/QVD), to damage mitochondria and promote mtDNA release³³, was used as a positive
196 control. Notably, in primary fibroblasts of a patient with a heterozygous R99C mutation in ARF1
197 (#Patient 1), cytoplasmic mtDNA levels were significantly elevated compared to control ARF1
198 WT donor fibroblasts (n2, f1, I7) (Fig. 3e). Depletion of mtDNA using 2',3' dideoxycytidine
199 (ddC)³⁴ in U2OS-STING cells reduced the induction of the ISG OAS1 in the presence of ARF1
200 R99C (Fig. 3f, Extended Data Fig. 3b). In line with this, gene expression of *IFNB1*, *Mx1* and
201 *RSAD2* induced by ARF1 R99C expression was also reduced upon mtDNA depletion (Extended
202 Data Fig. 3d-f). Of note, mtDNA depletion did not change the response to herring testis DNA (HT-
203 DNA) (Extended Data Fig. 3c).

204 In summary, these data show that expression of ARF1 R99C promotes mitochondrial disruption
205 and leakage of mtDNA into the cytoplasm, and a subsequent induction of ISG expression.

206 **ARF1 R99C destabilizes mitochondria by interfering with mitochondrial fusion**

207 Since ARF1 has been reported to be involved in mitophagy (i.e. autophagic turnover of defective
208 mitochondria), and in the regulation of mitochondrial fusion and fission^{29,35}, an impairment of
209 either process by ARF1 R99C might cause aberrant mtDNA release via disturbed mitochondrial
210 homeostasis³⁶⁻³⁸. Thus, we explored whether mitophagy is altered by ARF1 R99C, with
211 subsequent impact on mtDNA release. In the presence of both ARF1 WT and R99C,
212 autophagosomes accumulated in HEK293T GFP-LC3B reporter cells (Extended data Fig. 3g).
213 Bafilomycin A1 treatment masked the effect of both ARF1 WT and R99C, suggesting that both
214 proteins reduce autophagosome turnover (Extended data Fig. 3h). Notably, in autophagy-impaired
215 ATG5 KO cells, ARF1 R99C still mediated mtDNA release compared to WT and vector

216 conditions (Extended data Fig. 3i), suggesting that a defect in autophagy is not responsible for
217 mtDNA release in the presence of ARF1 R99C. Mitotracker staining of mitochondria in
218 transfected HeLa cells revealed a significant reduction in the mitochondrial footprint in the
219 presence of ARF1 R99C (Extended data Fig. 3j, k), indicating mitochondrial fragmentation due to
220 a change in mitochondrial fission or fusion. Analysis of phosphorylated (activation) levels of the
221 mitochondrial fission factor Drp1 revealed no change in the presence of ARF1 R99C (Extended
222 data Fig. 3l). In contrast, the mitochondrial fusion marker mitofusin 1 (MFN1) accumulated
223 significantly in the presence of ARF1 R99C but not ARF1 WT (Fig. 3g). In yeast, ARF1 deficiency
224 leads to Fzo1 (yeast equivalent of MFN1/2) misfolding and aggregation²⁹. Thus, accumulation of
225 MFN1 upon ARF1 R99C expression suggests that mitochondrial fusion is impaired. Consistently,
226 ER-mitochondria contacts, that are dependent on proper mitochondrial fusion, were visibly
227 increased (Fig. 3b). To understand whether this impacts mtDNA release by ARF1 R99C, we
228 promoted MFN1 turnover by overexpression of the E3 ubiquitin ligase Valosin Containing Protein
229 (VCP)²⁹. Notably, overexpression of VCP reduced mtDNA release induced by ARF1 R99C almost
230 back to basal levels (Fig. 3h, i).

231 Taken together, these data indicate that ARF1 R99C prevents proper fusion of mitochondria by
232 interfering with MFN1 function, leading to a leakage of mtDNA into the cytoplasm.

233 **Mutation of R99 impairs ARF1 GTPase activity and association with the COPI complex**

234 ARF1 is a small GTPase, and both GTP-GDP cycling and co-factor binding are known to be
235 crucial for its enzymatic activity¹⁸. Analyses of ARF1 structures, based on PDB: 2J59³⁹, indicated
236 that residue R99 is not directly involved in binding to GTP or other ARF1 interaction partners.
237 Instead, R99, located on helix $\alpha 5$, forms salt bridges with residue D26, thereby stabilizing the loop
238 $\beta 1$ - $\alpha 3$ which is part of the GTP-binding site of ARF1 (Fig. 4a). D26 is not directly involved in the

239 coordination of GTP binding (Fig. 4a). However, the correct positioning of the loop β 1- α 3 is
240 crucial for the stability of ARF1 and GTP hydrolysis³⁹. To experimentally assess the effects of the
241 R99C mutation on protein stability, GTP binding and GTP hydrolysis, we purified recombinant
242 ARF1 WT, ARF1 R99C and ARF1 Q71L (Extended Data Fig. 4a), and performed comparative
243 fluorescence thermal shift assays as well as *in vitro* GTPase assays. Both ARF1 WT and R99C
244 proteins bind GTP with similar affinity, as revealed by an increase of the melting temperatures by
245 ~16°C of both proteins in the presence of GTP (Fig. 4b, c). However, a 15°C lower melting
246 temperature of ARF1 R99C compared to ARF1 WT or ARF1 Q71L, indicates reduced
247 conformational stability (Extended Data Fig. 4b). Consequently, the *in vitro* GTPase activity of
248 ARF1 R99C was significantly lower than that of WT ARF1 (Fig. 4d). Of note, reduced
249 conformational stability does not lead to low expression levels of ectopically expressed R99C
250 ARF1, which would be indicative of an unstable protein (Figs. 2-4). Additionally, ARF1
251 dimerization, known to be required for vesicle transport activity and GTP hydrolysis^{18,40}, was
252 similar between mutant and WT ARF1 (Extended Data Fig. 4c). To promote the GTPase activity
253 of ARF1 R99C, we co-expressed mutant ARF1 with the ARF1 GTPase activating protein (GAP)
254 ARFGAP1, and with the GTP exchange factor (GEF) BIG1²². Accelerating GTPase activity by a
255 GAP, or increasing GDP/GTP exchange by a GEF, rescued aberrant type I IFN induction by ARF1
256 R99C in 293-Dual-hSTING-R232 cells (Fig. 4e).

257 Destabilization of ARF1 may also result in decreased binding to important effectors and co-factors.
258 To explore this possibility, we performed stable isotope labelling of amino acids in cell culture
259 (SILAC) mass spectrometry experiments, comparing the interaction of endogenous proteins to
260 either ARF1 WT or ARF1 R99C expressed in HEK293T cells, in heavy and light arginine
261 containing media, respectively (Extended Data Fig. 4d). Proteins were purified while maintaining
262 endogenous interaction partners (Extended Data Fig. 4e), and ~1900 co-purified proteins were

263 identified by mass spectrometry analysis of the lysates (Supplementary table 2, Fig. 4f). Notably,
264 all major protein components of COPI complex (COPA, COPB1, COPB2, COPD/ARCN1, COPE,
265 COPG1, COPG2 and COPS8) showed on average a ~3400-fold lower association with ARF1
266 R99C. Panther DB aided Gene Ontology (GO) term analysis of the top 100 proteins binding with
267 lower affinity to ARF1 R99C confirmed that interaction with proteins of the COPI pathway was
268 significantly affected (GoTerm: COPI vesicle coat (GO:0030126), >100-fold (maximum)
269 downregulation, $p = 4.85E-12$; COPI-coated vesicle membrane (GO:0030663), 76.99-fold
270 downregulation, $p = 2.94E-11$; COPI-coated vesicle (GO:0030137), 62.99-fold downregulation, p
271 $= 9.41E-11$) (Fig. 4g).

272 Altogether, biochemical characterization revealed that R99C reduced conformational stability,
273 GTPase activity and association with components of the COPI complex of ARF1.

274 **ARF1 is required for retrograde transport from the ERGIC to the ER**

275 To understand whether the reduced association of ARF1 R99C with components of the COPI
276 transport machinery might affect STING trafficking and signaling directly, we sought to activate
277 STING independently of cGAS. Indeed, bypassing the requirement for cGAS by treatment with
278 cGAMP showed that ARF1 R99C further enhances IFN signaling compared to WT ARF1 (Fig.
279 5a, b). Consistently, we observed elevated IFN signalling in the presence of ARF1 R99C upon
280 expression of an active STING mutant (R238A/Y240A) that does not bind or require cGAMP^{41,42}
281 (Fig. 5c). As expected, STING with a mutation in S366A, that is unable to bind to TBK1, did not
282 induce type I IFN signaling, despite being expressed at similar levels to WT STING (Extended
283 Data Fig. 5b). Neither ARF1 WT nor R99C caused further signaling activation. The above results
284 suggest that, in addition to dysfunction of ARF1 in limiting mtDNA leakage to the cytoplasm,
285 ARF1 R99C also enhances type I IFN signalling through changes in STING trafficking and

286 signalling downstream of cGAS/cGAMP. As STING recycling has been proposed to occur by
287 retrograde transport via COPI vesicles¹⁴⁻¹⁷, we then asked if the decreased association of ARF1
288 R99C with COPI vesicles might result in decreased STING recycling, and thus impaired signal
289 termination of STING and prolonged IFN induction. To this end, we explored the impact of
290 patient-associated mutant ARF1 on retrograde Golgi/ERGIC-ER transport. Electron microscopy
291 analysis revealed that ARF1 R99C expression led to altered Golgi/ERGIC structures, whereas
292 empty vector or ARF1 WT transfection had no effect (Fig. 5d). Indeed, scanning-transmission-
293 electron-microscopy (STEM) tomography analysis revealed that, in the presence of ARF1 R99C,
294 the volume density of the lumen of the Golgi is increased (Fig. 5e), whereas the volume density of
295 vesicles released from the Golgi and the ER is significantly reduced compared to ARF1 WT (Fig.
296 5f). Focusing on the ERGIC, confocal microscopy analysis confirmed the alteration of Golgi
297 structure. Specifically, it showed that the number of ERGIC-53 positive vesicles per cell i.e.
298 ERGIC vesicles, was significantly reduced in the presence of ARF1 R99C and ARF1 Q71L (Fig.
299 5g, left panel, Extended Data Fig. 5c). Conversely, the area occupied by individual ERGIC-53
300 positive structures was increased upon ARF1 R99C and Q71L expression (Fig. 5g, middle panel),
301 while the total area of the ERGIC-53 positive structures per cell did not change (Fig. 5g, right
302 panel). Thus, in the presence of ARF1 R99C, fewer but larger vesicles/ERGIC structures are
303 present, suggesting impaired budding of vesicles from the ERGIC. To examine whether ARF1
304 R99C impacts general ERGIC to ER trafficking, we used a thermolabile VSV-G protein fused to
305 the KDEL retrograde trafficking signal⁴³. Upon decreasing the temperature to 32°C, the normally
306 ER-resident construct is transported to the Golgi, while shifting to 40°C partially unfolds VSV-G
307 thereby inducing retrograde transport back to the ER. Both ARF1 WT and R99C expression did
308 not impact VSV-G increased co-localisation with the cis-Golgi (marker GM130) upon lowering
309 the temperature (Fig. 5h, Extended Data Fig. 5d). However, when raising the temperature to 40°C,

310 retrograde transport was almost completely abrogated in the presence of ARF1 R99C, but
311 unaffected by ARF1 WT expression (Fig. 5h).

312 In summary, the above data demonstrate that ARF1 R99C causes a defect in Golgi-ER retrograde
313 trafficking and reduced vesicular budding from the Golgi/ERGIC.

314 **Active STING is trapped at the Golgi/ERGIC by ARF1 R99C**

315 To examine the consequences of defective retrograde transport on STING in the presence of ARF1
316 R99C, we examined the co-localisation of ARF1 and STING-eGFP in HeLa cells relative to
317 endogenous markers of the Golgi network (Fig. 6a-f, Extended Data Fig. 6a-c). As controls, ARF1
318 Q71L is expected to show increased membrane association with the Golgi/ERGIC, whereas ARF1
319 T31N is thought to be more cytoplasmic¹⁸. While ARF1 WT, R99C and Q71L localised similarly
320 to the cis-Golgi as revealed by co-localisation with GM130, ARF1 T31N showed a reduced co-
321 localisation with GM130 (Fig. 6a, b). Notably, expression of both ARF1 R99C and Q71L led to a
322 significant increase of eGFP-STING localization at the cis-Golgi signal compared to WT and
323 T31N ARF1 (Fig. 6a, c). Analysis of ERGIC localisation revealed that ARF1 R99C and Q71L
324 showed markedly increased co-localisation with the ERGIC compared to ARF1 WT (Extended
325 Data Fig. 6a-c). Consistent with this, expression of ARF1 R99C and Q71L significantly increased
326 the co-localisation between eGFP-STING and ERGIC-53, whereas ARF1 WT and T31N had little
327 or no impact on STING localisation at the ERGIC (Extended Data Fig. 6a-c). The presence of
328 ARF1 R99C did not alter the localization of eGFP-STING with respect to the trans-Golgi network
329 (TGN46) (Extended Data Fig. 6d-f). In primary fibroblasts from a healthy donor (genotype ARF1
330 WT), endogenous STING only accumulates at the Golgi network (GM130) upon stimulation with
331 cGAMP (Fig. 6d, e). In contrast, in fibroblasts from a patient heterozygous for the R99C mutation
332 in ARF1 (#Patient 1), STING accumulated at the cis-Golgi/ERGIC even in the absence of cGAMP
333 stimulation. This is consistent with the data from our cell line experiments (Fig. 6d, e). To analyze

334 the effect of ARF1 mutants on the localization of endogenous STING in more detail, we employed
335 super-resolution microscopy (stimulated emission/depletion microscopy, STED). Two colour
336 STED microscopy in primary human lung fibroblasts transduced with empty, ARF1 WT or ARF
337 R99C expressing lentiviruses confirmed that, in the presence of ARF1 R99C, endogenous STING
338 accumulates at/around the cis-Golgi (GM130) network (exemplary image in Fig. 6f, further images
339 in Extended Data Fig. 6g).

340 To determine whether STING accumulates in its active state at the Golgi/ERGIC, we co-stained
341 phospho-TBK1 (p-S172) as a marker of STING activity *in situ*. Confocal analysis revealed that in
342 the presence of transduced ARF1 R99C, but not ARF1 WT, increased amounts of activated TBK1
343 were present in the proximity of the ERGIC in primary human lung fibroblasts (Fig. 6g, h).

344 Taken together, these results suggest that ARF1 plays a role in the retrograde transport of STING
345 from the Golgi/ERGIC to the ER. When trafficking is affected due to impaired ARF1 GTPase
346 activity (e.g. by mutations at R99C or Q71L), STING accumulates at the cis-Golgi/ERGIC in both
347 cell models and primary cells isolated from patients, leading to activation of TBK1 and sustained
348 IFN induction/signalling.

349 **DISCUSSION**

350 The avoidance of chronic activation of a type I IFN response is fundamental to immunological
351 homeostasis⁴. Engagement of the cGAS-STING pathway occurs through the recognition of DNA
352 by cGAS ('Trigger'), and subsequent trafficking of STING from the ER to the Golgi. To terminate
353 such signalling, STING is transported back to the ER ('Recycling') and degraded via autophagy
354 ('Removal'). Through an analysis of the function of an ARF1 mutant associated with elevated IFN
355 signalling *in vivo*, we have identified a previously unrecognised dual role of the GTPase ARF1 in
356 both preventing aberrant cGAS activation and promoting signal termination by the recycling of

357 STING (Extended Data Fig 7). We show that functional ARF1 promotes proper mitochondrial
358 fusion, thereby preventing aberrant stimulation of cGAS by mtDNA. In addition, we demonstrate
359 a role for ARF1 in the termination of cGAS-STING signalling, by facilitating COPI vesicle-
360 mediated trafficking of STING from the ERGIC to the ER. When the GTPase activity of ARF1 is
361 impaired, either by disease-associated mutations at R99 or by the characterised GTP-locked Q71L
362 mutation, type I IFN responses are enhanced. Consequently, patients bearing a heterozygous R99
363 mutation in ARF1 manifest features of chronic innate immune activation.

364 Complete disruption (e.g. by drugs such as Brefeldin A) or depletion of ARF1 is well known to
365 decrease STING-dependent signalling^{11,12,44}. This effect is most likely due to a generalised
366 disturbance of the Golgi structure/transporting system⁴⁵, including the anterograde transport of
367 STING required for its activation. In contrast, our investigation of a physiologically relevant
368 human interferonopathy-associated ARF1 mutant has allowed us to define an ARF1-specific effect
369 on retrograde STING trafficking thus differentiating it from a non-specific effect on anterograde
370 transport.

371 GTPases are core components involved in the regulation of mitochondrial fission and fusion that
372 include MFN1, MFN2, and OPA1. A role of ARF1 in regulating Fzo1 (the yeast MFN1
373 homologue) was previously proposed in yeast⁴⁶. In the absence of functional ARF1, Fzo1
374 accumulated, leading to a loss of mitochondrial fusion. Our data show that human ARF1 also
375 regulates mitochondrial fusion. Thus, non-functional ARF1 leads to impaired mitochondrial
376 integrity and aberrant accumulation of MFN1. The human homologue of yeast Fzo1 associated E3
377 ubiquitin ligase cdc48, VCP, was able to resolve the mitochondrial fusion impairment consequent
378 upon defective ARF1. These data suggest that ARF1 plays an important role in mitochondrial
379 fusion and fission in mammals. Of note, it was recently shown that Golgi-derived vesicles may aid
380 mitochondrial fusion and fission, spatially linking ARF1 and mitochondria^{30,47}.

381 Previous work has shown that defects in retrograde transport can mediate chronic type I IFN
382 release in a cGAS dependent¹⁷ or independent fashion¹⁴. Our mechanistic analyses indicate that
383 IFN induction in patients with ARF1 R99C is dependent on cGAS activity. Given impaired
384 mitochondrial integrity in both model and patient cells, our data suggest that, even in the absence
385 of a pathogen-derived cGAS trigger, ARF1 dysfunction may lead to sterile inflammation. The
386 relative contribution of defects in mitochondrial maintenance and retrograde transport of STING
387 to an ARF1-dependent type I interferonopathy disease-state remains to be determined. Although
388 each process may be sufficient to cause disease^{14,15,48}, it is possible that these two aberrant activities
389 drive the mutant-associated phenotype synergistically, i.e. stimulation of the cGAS-STING
390 pathway via mtDNA is further exacerbated by defective signal termination. Improper termination
391 of cGAS-STING triggering in the presence of ARF1 R99C, e.g. after exogenous triggers like viral
392 infection, might accelerate and aggravate disease progression. Future studies dissecting the
393 different functions of ARF1 in the regulation of the IFN response to infectious diseases, and the
394 molecular mechanism by which ARF1 maintains mitochondrial integrity, are warranted.

395 Our data add to the emerging evidence that impaired control of cGAS-STING signal activation
396 and termination is central to the pathogenesis of a number of type I interferonopathies⁴. The first
397 described example of a Mendelian disease associated with chronic type I IFN signalling was
398 Aicardi-Goutières syndrome (AGS). Mutations in TREX1, the RNase H2 complex, the
399 deoxynucleoside triphosphate triphosphohydrolase SAMHD1 and the U7 small nuclear RNP
400 complex all result in IFN induction by self DNA⁴. Recently, we described pathogenic mutations
401 in mitochondrial ATPase family AAA domain-containing protein 3A (ATAD3A) to result in a
402 leakage of mtDNA into the cytosol⁴⁸. Furthermore, defects in STING trafficking along the ER-
403 Golgi axis have been reported to underlie various type I interferonopathy diseases. For example,
404 activating mutations in STING cause SAVI⁴⁹⁻⁵¹, where *in vitro* studies revealed that mutations in

405 the oligomerisation interface of STING (e.g. N154S, V155M and V147L, G207E, R281Q, R284G
406 and R284S) result in spontaneous cGAMP-independent accumulation of STING at the Golgi, and
407 aberrant induction of type I IFN signalling. Related to this, dysregulation of STING retrieval from
408 the Golgi, due to heterozygous missense mutations in a component of COPI, coatamer protein
409 subunit alpha (COPA), lead to enhanced type I IFN signalling^{14,15,52}. Here, STING has been
410 suggested to be recruited to COPA-containing COPI vesicles via SURF4^{15,17}, although other
411 players may also be involved in regulating and triggering retrograde transport of STING. Besides
412 recycling as a mechanism of signal termination, active STING is captured for subsequent
413 autophagy-dependent degradation^{11,13,53}. Recently, it was shown that ARF1 may also have a role
414 in autophagy. However, our data show that cGAS-STING activation by the ARF1 R99C mutation
415 is not mediated by autophagy⁵⁴. Future studies are needed to genetically dissect the relative
416 contribution of autophagy-mediated STING turnover and ARF1-mediated STING recycling to
417 overall cGAS/STING signal termination.

418 Our data indicate a general defect in retrograde trafficking in the presence of ARF1 R99C (Fig.
419 5g, h). Besides STING recycling, retrograde trafficking retrieves key factors required for ER
420 export^{55,56}, and is central to ER and Golgi homeostasis⁵⁷. It is possible that non-IFN mediated
421 mechanisms also contribute to the disease phenotype reported here. That being said, the recording
422 of elevated levels of ISGs in patient blood, and the skin lesions present in three of the four cases
423 that we ascertained (Fig. 1), are highly characteristic of other Mendelian type I
424 interferonopathies^{4,5}. Some functions of ARF1 are redundant and may be compensated by other
425 ARF proteins^{55,58,59}. However, any such compensation is clearly insufficient in the case of the
426 heterozygous mutations at R99 of ARF1. We speculate that homozygous spontaneous mutations
427 of ARF1 would not be viable. Of note, similar to other interferonopathies with a defect in STING
428 trafficking, such as the COPA syndrome, one defective allele is sufficient for disease¹⁴. Thus,

429 ARF1 R99C and other disease-causing mutations in the STING trafficking pathway may act in a
430 dominant negative fashion in regards to DNA sensing, while the heterozygous presence of WT
431 ARF1 may be sufficient to maintain organismal viability.

432 In summary, through an exploration of the mechanistic basis of a novel human type I
433 interferonopathy, our data establish key roles of the small GTPase ARF1 in both ensuring
434 mitochondrial fusion and in Golgi-ER retrograde STING trafficking to prevent aberrant cGAS-
435 STING pathway activity. These data highlight the importance of recycling mechanisms in innate
436 immune homeostasis, and provide first evidence towards involvement of Golgi-associated ARF
437 GTPases in mitochondrial integrity. Further, our results may inform a targeted treatment approach
438 to the ARF-dependent type I interferonopathy state.

439

440 **ACKNOWLEDGEMENTS**

441 We thank Jana-Romana Fischer, Birgit Ott, Regina Burger, Daniela Krnavek, Kerstin
442 Regensburger, Martha Meyer and Nicola Schrott for excellent technical assistance. This study was
443 supported by DFG (German Research Foundation) grants SP1600/4-1 (to KMJS), SPP1923 (to
444 KMJS and FK), CRC1279 (to KMJS, FK, JM, CR, SW and PW), as well as the BMBF to FK
445 (Restrict SARS-CoV-2) and KMJS (IMMUNOMOD) and Emmy Noether Programme 458004906
446 to CCOM. YJC sincerely thanks Mathieu Rodero, Tatiana Moreau, Elizabeth Sztul and Paul
447 Randazzo for the generation of early preliminary data not included in the manuscript, and Marine
448 Depp and Carolina Ugenti for providing the eGFP-STING plasmid. YJC also thanks Paolo
449 Piccolo for expert clinical phenotyping, Ignazia Prigione for experimental support, Gillian Rice
450 for deriving interferon scores, and Jean-Madeleine de Sainte Agathe for clinical advice. YJC
451 acknowledges the European Research Council (786142 E-T1IFNs), a state subsidy from the

452 Agence Nationale de la Recherche (France) under the ‘Investissements d’avenir’ program bearing
453 the reference ANR-10-IAHU-01, and MSDAVENIR (Devo-Decode Project). This study makes
454 use of data generated by the DECIPHER community, with a full list of contributing centres
455 available at <http://deciphergenomics.org/about/stats> and via email from
456 contact@deciphergenomics.org. Funding for the DECIPHER project was provided by the
457 Wellcome Trust. AL acknowledges Inserm International Research Project (Inserm IRP) program.
458 MH, LK, SK and VH are part of the international graduate school in molecular medicine, Ulm
459 (IGradU).

460 **AUTHOR CONTRIBUTIONS**

461 YJC, AL, MH and KMJS conceived the project, and designed and interpreted experiments. MH
462 performed most of the experiments. AL, VH, LK, SK, VM, BDB performed additional
463 experiments. UR, TB, CR and PW contributed the electron microscopy studies. FW and JM
464 provided superresolution imaging. VM and CCdOM performed and planned the *in vitro*
465 experiments. CCdOM, JM, FK supervised experiments and helped interpret data. SV, MG, RP,
466 SAL, MGH, GH, KMW, JS, JL contributed patient data. YJC, AL, MH and KMJS wrote the
467 manuscript.

468 **DECLARATIONS OF INTERESTS**

469 All authors declare no competing interests.

470 **REFERENCES**

- 471 1. Schoggins, J. W. Interferon-Stimulated Genes: What Do They All Do? *Annu. Rev. Virol.* **6**,
472 567–584 (2019).
- 473 2. Sparrer, K. M. J. & Gack, M. U. Intracellular detection of viral nucleic acids. *Curr. Opin.*
474 *Microbiol.* **26**, 1–9 (2015).

- 475 3. Koepke, L., Gack, M. U. & Sparrer, K. M. The antiviral activities of TRIM proteins. *Curr.*
476 *Opin. Microbiol.* **59**, 50–57 (2021).
- 477 4. Crow, Y. J. & Stetson, D. B. The type I interferonopathies: 10 years on. *Nat. Rev. Immunol.*
478 1–13 (2021) doi:10.1038/s41577-021-00633-9.
- 479 5. Crow, Y. J. Type I interferonopathies: a novel set of inborn errors of immunity. *Ann. N. Y.*
480 *Acad. Sci.* **1238**, 91–98 (2011).
- 481 6. Ablasser, A. & Chen, Z. J. cGAS in action: Expanding roles in immunity and inflammation.
482 *Science* **363**, eaat8657 (2019).
- 483 7. Hopfner, K.-P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-
484 STING signalling. *Nat. Rev. Mol. Cell Biol.* **21**, 501–521 (2020).
- 485 8. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP Synthase is a Cytosolic
486 DNA Sensor that Activates the Type-I Interferon Pathway. *Science* **339**, (2013).
- 487 9. Gao, D. *et al.* Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune
488 diseases. *Proc. Natl. Acad. Sci.* **112**, E5699–E5705 (2015).
- 489 10. Wu, J. *et al.* Cyclic GMP-AMP is an endogenous second messenger in innate immune
490 signaling by cytosolic DNA. *Science* **339**, 826–830 (2013).
- 491 11. Gui, X. *et al.* Autophagy induction via STING trafficking is a primordial function of the
492 cGAS pathway. *Nature* **567**, 262–266 (2019).
- 493 12. Dobbs, N. *et al.* STING Activation by Translocation from the ER Is Associated with
494 Infection and Autoinflammatory Disease. *Cell Host Microbe* **18**, 157–168 (2015).
- 495 13. Gonugunta, V. K. *et al.* Trafficking-Mediated STING Degradation Requires Sorting to
496 Acidified Endolysosomes and Can Be Targeted to Enhance Anti-tumor Response. *Cell Rep.*
497 **21**, 3234–3242 (2017).

- 498 14. Lepelley, A. *et al.* Mutations in COPA lead to abnormal trafficking of STING to the Golgi
499 and interferon signaling. *J. Exp. Med.* **217**, e20200600 (2020).
- 500 15. Deng, Z. *et al.* A defect in COPI-mediated transport of STING causes immune dysregulation
501 in COPA syndrome. *J. Exp. Med.* **217**, e20201045 (2020).
- 502 16. Steiner, A. *et al.* Deficiency in coatamer complex I causes aberrant activation of STING
503 signalling. *Nat. Commun.* **13**, 2321 (2022).
- 504 17. Mukai, K. *et al.* Homeostatic regulation of STING by retrograde membrane traffic to the ER.
505 *Nat. Commun.* **12**, 61 (2021).
- 506 18. Bento, C. F., Puri, C., Moreau, K. & Rubinsztein, D. C. The role of membrane-trafficking
507 small GTPases in the regulation of autophagy. *J. Cell Sci.* **126**, 1059–1069 (2013).
- 508 19. Pennauer, M., Buczak, K., Prescianotto-Baschong, C. & Spiess, M. Shared and specific
509 functions of Arfs 1-5 at the Golgi revealed by systematic knockouts. *J. Cell Biol.* **221**,
510 e202106100 (2022).
- 511 20. Kahn, R. A. Toward a model for Arf GTPases as regulators of traffic at the Golgi. *FEBS*
512 *Lett.* **583**, 3872–3879 (2009).
- 513 21. Aikawa, Y. & Martin, T. F. J. ARF6 regulates a plasma membrane pool of
514 phosphatidylinositol(4,5)bisphosphate required for regulated exocytosis. *J. Cell Biol.* **162**,
515 647–659 (2003).
- 516 22. Sztul, E. *et al.* ARF GTPases and their GEFs and GAPs: concepts and challenges. *Mol. Biol.*
517 *Cell* **30**, 1249–1271 (2019).
- 518 23. Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for
519 connecting investigators with an interest in the same gene. *Hum. Mutat.* **36**, 928–930 (2015).
- 520 24. Goldberg, J. Structural basis for activation of ARF GTPase: mechanisms of guanine
521 nucleotide exchange and GTP-myristoyl switching. *Cell* **95**, 237–248 (1998).

- 522 25. Ge, X. *et al.* Missense-depleted regions in population exomes implicate ras superfamily
523 nucleotide-binding protein alteration in patients with brain malformation. *NPJ Genomic*
524 *Med.* **1**, 16036 (2016).
- 525 26. Dascher, C. & Balch, W. E. Dominant inhibitory mutants of ARF1 block endoplasmic
526 reticulum to Golgi transport and trigger disassembly of the Golgi apparatus. *J. Biol. Chem.*
527 **269**, 1437–1448 (1994).
- 528 27. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates
529 innate immune signalling. *Nature* **455**, 674–678 (2008).
- 530 28. Yum, S., Li, M., Fang, Y. & Chen, Z. J. TBK1 recruitment to STING activates both IRF3
531 and NF- κ B that mediate immune defense against tumors and viral infections. *Proc. Natl.*
532 *Acad. Sci.* **118**, e2100225118 (2021).
- 533 29. Ackema, K. B. *et al.* The small GTPase Arf1 modulates mitochondrial morphology and
534 function. *EMBO J.* **33**, 2659–2675 (2014).
- 535 30. Nagashima, S. *et al.* Golgi-derived PI(4)P-containing vesicles drive late steps of
536 mitochondrial division. *Science* **367**, 1366–1371 (2020).
- 537 31. Huang, L. S. *et al.* mtDNA Activates cGAS Signaling and Suppresses the YAP-Mediated
538 Endothelial Cell Proliferation Program to Promote Inflammatory Injury. *Immunity* **52**, 475-
539 486.e5 (2020).
- 540 32. West, A. P. *et al.* Mitochondrial DNA stress primes the antiviral innate immune response.
541 *Nature* **520**, 553–557 (2015).
- 542 33. White, M. J. *et al.* Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I
543 IFN Production. *Cell* **159**, 1549–1562 (2014).
- 544 34. Nelson, I., Hanna, M. G., Wood, N. W. & Harding, A. E. Depletion of mitochondrial DNA
545 by ddC in untransformed human cell lines. *Somat. Cell Mol. Genet.* **23**, 287–290 (1997).

- 546 35. Rabouille, C. Old dog, new tricks: Arf1 required for mitochondria homeostasis. *EMBO J.* **33**,
547 2604–2605 (2014).
- 548 36. Rai, P. *et al.* IRGM1 links mitochondrial quality control to autoimmunity. *Nat. Immunol.* **22**,
549 312–321 (2021).
- 550 37. Willemsen, J. *et al.* TNF leads to mtDNA release and cGAS/STING-dependent interferon
551 responses that support inflammatory arthritis. *Cell Rep.* **37**, 109977 (2021).
- 552 38. Bao, D. *et al.* Mitochondrial fission-induced mtDNA stress promotes tumor-associated
553 macrophage infiltration and HCC progression. *Oncogene* **38**, 5007–5020 (2019).
- 554 39. Ménétrey, J. *et al.* Structural basis for ARF1-mediated recruitment of ARHGAP21 to Golgi
555 membranes. *EMBO J.* **26**, 1953–1962 (2007).
- 556 40. Brumm, S. *et al.* Coordinated Activation of ARF1 GTPases by ARF-GEF GNOM Dimers Is
557 Essential for Vesicle Trafficking in Arabidopsis. *Plant Cell* **32**, 2491–2507 (2020).
- 558 41. Li, S. *et al.* Prolonged activation of innate immune pathways by a polyvalent STING agonist.
559 *Nat. Biomed. Eng.* **5**, 455–466 (2021).
- 560 42. He, Y. *et al.* Self-assembled cGAMP-STING Δ TM signaling complex as a bioinspired
561 platform for cGAMP delivery. *Sci. Adv.* **6**, eaba7589 (2020).
- 562 43. Cole, N. B., Ellenberg, J., Song, J., DiEuliis, D. & Lippincott-Schwartz, J. Retrograde
563 Transport of Golgi-localized Proteins to the ER. *J. Cell Biol.* **140**, 1–15 (1998).
- 564 44. Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS–STING pathway as a
565 therapeutic target in inflammatory diseases. *Nat. Rev. Immunol.* **21**, 548–569 (2021).
- 566 45. Wood, S. A., Park, J. E. & Brown, W. J. Brefeldin A causes a microtubule-mediated fusion
567 of the trans-Golgi network and early endosomes. *Cell* **67**, 591–600 (1991).
- 568 46. Ackema, K. B. *et al.* The small GTPase Arf1 modulates mitochondrial morphology and
569 function. *EMBO J.* **33**, 2659–2675 (2014).

- 570 47. Rasmussen, M. L., Robertson, G. L. & Gama, V. Break on Through: Golgi-Derived Vesicles
571 Aid in Mitochondrial Fission. *Cell Metab.* **31**, 1047–1049 (2020).
- 572 48. Lepelley, A. *et al.* Enhanced cGAS-STING-dependent interferon signaling associated with
573 mutations in ATAD3A. *J. Exp. Med.* **218**, e20201560 (2021).
- 574 49. Frémond, M.-L. *et al.* Overview of STING-Associated Vasculopathy with Onset in Infancy
575 (SAVI) Among 21 Patients. *J. Allergy Clin. Immunol. Pract.* **9**, 803-818.e11 (2021).
- 576 50. Jeremiah, N. *et al.* Inherited STING-activating mutation underlies a familial inflammatory
577 syndrome with lupus-like manifestations. *J. Clin. Invest.* **124**, 5516–5520 (2014).
- 578 51. Liu, Y. *et al.* Activated STING in a Vascular and Pulmonary Syndrome. *N. Engl. J. Med.*
579 **371**, 507–518 (2014).
- 580 52. Watkin, L. B. *et al.* COPA mutations impair ER-Golgi transport causing hereditary
581 autoimmune-mediated lung disease and arthritis. *Nat. Genet.* **47**, 654–660 (2015).
- 582 53. Prabakaran, T. *et al.* Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-
583 dependent autophagy pathway activated by TBK1. *EMBO J.* **37**, e97858 (2018).
- 584 54. Jia, M. *et al.* Myristic acid as a checkpoint to regulate STING-dependent autophagy and
585 interferon responses by promoting N-myristoylation. *Nat. Commun.* **14**, 660 (2023).
- 586 55. Adarska, P., Wong-Dilworth, L. & Bottanelli, F. ARF GTPases and Their Ubiquitous Role in
587 Intracellular Trafficking Beyond the Golgi. *Front. Cell Dev. Biol.* **9**, (2021).
- 588 56. Gilbert, C. E., Sztul, E. & Machamer, C. E. Commonly used trafficking blocks disrupt ARF1
589 activation and the localization and function of specific Golgi proteins. *Mol. Biol. Cell* **29**,
590 937–947 (2018).
- 591 57. Spang, A. Retrograde Traffic from the Golgi to the Endoplasmic Reticulum. *Cold Spring*
592 *Harb. Perspect. Biol.* **5**, a013391 (2013).

- 593 58. Nakai, W. *et al.* ARF1 and ARF4 regulate recycling endosomal morphology and retrograde
594 transport from endosomes to the Golgi apparatus. *Mol. Biol. Cell* **24**, 2570–2581 (2013).
- 595 59. Sumiyoshi, M. *et al.* Arf1 and Arf6 Synergistically Maintain Survival of T Cells during
596 Activation. *J. Immunol.* **206**, 366–375 (2021).
- 597 60. Presley, J. F. *et al.* ER-to-Golgi transport visualized in living cells. *Nature* **389**, 81–85
598 (1997).
- 599 61. Hayn, M. *et al.* Systematic functional analysis of SARS-CoV-2 proteins uncovers viral
600 innate immune antagonists and remaining vulnerabilities. *Cell Rep.* **35**, 109126 (2021).
- 601 62. Koepke, L. *et al.* An improved method for high-throughput quantification of autophagy in
602 mammalian cells. *Sci. Rep.* (2020) doi:10.1038/s41598-020-68607-w.
- 603 63. Hirschenberger, M. *et al.* Luciferase reporter assays to monitor interferon signaling
604 modulation by SARS-CoV-2 proteins. *STAR Protoc.* **2**, 100781 (2021).
- 605 64. Diemen, F. R. van *et al.* CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits
606 Productive and Latent Infections. *PLOS Pathog.* **12**, e1005701 (2016).
- 607 65. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for
608 CRISPR screening. *Nat. Methods* **11**, 783–784 (2014).
- 609 66. Bryant, J. D., Lei, Y., VanPortfliet, J. J., Winters, A. D. & West, A. P. Assessing
610 Mitochondrial DNA Release into the Cytosol and Subsequent Activation of Innate Immune-
611 related Pathways in Mammalian Cells. *Curr. Protoc.* **2**, e372 (2022).
- 612 67. Rademaker, L. *et al.* Role of mutations and post-translational modifications in systemic AL
613 amyloidosis studied by cryo-EM. *Nat. Commun.* **12**, 6434 (2021).
- 614 68. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass
615 accuracies and proteome-wide protein quantification - PubMed.
616 <https://pubmed.ncbi.nlm.nih.gov/19029910/>.

- 617 69. Cox, J. *et al.* Andromeda: a peptide search engine integrated into the MaxQuant
618 environment. *J. Proteome Res.* **10**, 1794–1805 (2011).
- 619 70. Mi, H. *et al.* PANTHER version 16: a revised family classification, tree-based classification
620 tool, enhancer regions and extensive API. *Nucleic Acids Res.* **49**, D394–D403 (2021).
- 621 71. Mi, H. *et al.* Protocol Update for Large-scale genome and gene function analysis with
622 PANTHER Classification System (v.14.0). *Nat. Protoc.* **14**, 703–721 (2019).
- 623 72. Costes, S. V. *et al.* Automatic and Quantitative Measurement of Protein-Protein
624 Colocalization in Live Cells. *Biophys. J.* **86**, 3993–4003 (2004).
- 625 73. Valente, A. J., Maddalena, L. A., Robb, E. L., Moradi, F. & Stuart, J. A. A simple ImageJ
626 macro tool for analyzing mitochondrial network morphology in mammalian cell culture.
627 *Acta Histochem.* **119**, 315–326 (2017).
- 628 74. Osseforth, C., Moffitt, J. R., Schermelleh, L. & Michaelis, J. Simultaneous dual-color 3D
629 STED microscopy. *Opt. Express* **22**, 7028–7039 (2014).
- 630 75. Read, C., Schauflinger, M., Nikolaenko, D., Walther, P. & von Einem, J. Regulation of
631 Human Cytomegalovirus Secondary Envelopment by a C-Terminal Tetralysine Motif in
632 pUL71. *J. Virol.* **93**, e02244-18 (2019).
- 633 76. Walther, P. & Ziegler, A. Freeze substitution of high-pressure frozen samples: the visibility
634 of biological membranes is improved when the substitution medium contains water. *J.*
635 *Microsc.* **208**, 3–10 (2002).
- 636 77. Wieland, J. *et al.* Zika virus replication in glioblastoma cells: electron microscopic
637 tomography shows 3D arrangement of endoplasmic reticulum, replication organelles, and
638 viral ribonucleoproteins. *Histochem. Cell Biol.* **156**, 527–538 (2021).
- 639 78. Kremer, J. R., Mastronarde, D. N. & McIntosh, J. R. Computer Visualization of Three-
640 Dimensional Image Data Using IMOD. *J. Struct. Biol.* **116**, 71–76 (1996).

- 641 79. Weibel, E. R. Stereological Principles for Morphometry in Electron Microscopic
642 Cytology¹¹The personal work of the author was supported by Grant No. 3952 from the
643 Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, and by
644 Grant No. 78 from BIGA. in *International Review of Cytology* (eds. Bourne, G. H., Danielli,
645 J. F. & Jeon, K. W.) vol. 26 235–302 (Academic Press, 1969).
- 646 80. Sun, W., Vanhooke, J. L., Sondek, J. & Zhang, Q. High-throughput fluorescence polarization
647 assay for the enzymatic activity of GTPase-activating protein of ADP-ribosylation factor
648 (ARFGAP). *J. Biomol. Screen.* **16**, 717–723 (2011).
- 649 81. Ashkenazy, H. *et al.* ConSurf 2016: an improved methodology to estimate and visualize
650 evolutionary conservation in macromolecules. *Nucleic Acids Res.* **44**, W344–W350 (2016).

651

652

653 **FIGURE LEGENDS**

654 **Figure 1. Genetic Identification of ARF1 R99C and clinical phenotype. a-g**, Erythematous
655 vasculitic chilblain-like lesions on the hands (**a**) and face (**b**) of Patient 1. Right hand of the same
656 patient showing frank tissue loss (**c**). Similar lesions were observed on the hands and feet of
657 patients (**d**, **e**, **f**, **g**). **h**, Schematic overview of the domain structure of ARF1. Residue R99 is
658 indicated by a red arrow. SW, Switch domain. **i**, Multiple sequence alignment showing the
659 conservation of residue R99 of ARF1 in indicated species. **j**, ISG profile of patient Patient 2 (red)
660 compared to the average of 29 healthy donors (blue).

661

662 **Figure 2. Expression of ARF1 R99C induces a STING dependent type I IFN response. a**,
663 SEAP reporter gene assays to assess the impact of transient expression of FLAG-tagged ARF1

664 WT, R99C, Q71L or T31N on ISRE promoter induction in 293-Dual-hSTING-R232 reporter cells.
665 SEAP expression was quantified 32 hours (h) post transfection and normalised to cell viability.
666 Dots represent mean of $n = 3 \pm \text{SEM}$ (biological replicates). Lower panel: Corresponding
667 immunoblots of whole cell lysates (WCLs) showing the corresponding expression of ARF1 WT
668 R99C, Q71L and T31N stained with anti-FLAG. **b**, Area under the curve analysis of the data in
669 **(a)**. **c**, Impact of FLAG-tagged ARF1 WT and R99C expression by transient transfection on ISRE
670 promoter activity in HEK293T cells co-expressing STING (+STING) or empty vector (-STING).
671 ISRE-driven Firefly luciferase (Fluc) was quantified 32 h post transfection and normalised to
672 GAPDH-promoter driven Renilla luciferase. Dots represent mean of $n = 3 \pm \text{SEM}$ (biological
673 replicates). Lower panel: Corresponding immunoblots of WCLs showing the expression of ARF1
674 mutants, stained by anti-FLAG. **d**, Impact of ARF1 WT and R99C delivered by lentiviral
675 transduction on ISRE promoter activity in A549 Dual reporter cells. IFN- β (1000 U/mL, 16 h) and
676 cGAMP (10 $\mu\text{g/ml}$, 16 h) served as positive controls. Bars represent mean of $n = 3 \pm \text{SEM}$
677 (biological replicates). Lower panel: Corresponding immunoblots of WCLs stained by anti-FLAG,
678 anti-STING and anti-GAPDH. **e**, Impact of ARF1 WT and R99C delivered by lentiviral
679 transduction on NF- κB promoter activity in A549 Dual reporter cells quantified via SEAP activity.
680 IFN- β (1000 U/mL, 16 h) and cGAMP (10 $\mu\text{g/ml}$, 16 h) served as positive controls. Bars represent
681 mean of $n = 3 \pm \text{SEM}$ (biological replicates). Lower panel: Corresponding immunoblots of WCLs
682 stained by anti-FLAG, anti-STING and anti-GAPDH. **f**, Exemplary immunoblot of WCLs of
683 HEK293T cells transiently expressing vector or indicated ARF1 mutants as well as cGAS and
684 STING. Blots were stained with anti-pTBK1, anti-TBK1, anti-IRF3, anti-FLAG and anti-GAPDH.
685 **g**, Quantification of the band intensities in **(f)** for pTBK1 normalized to the band intensities of
686 TBK1, in the presence of cGAS/STING. Bars represent mean of $n = 3 \pm \text{SEM}$ (biological
687 replicates). **h**, Impact of ARF1 WT and R99C expression on ISG induction in primary normal

688 human lung fibroblasts (NHLF) as assessed by qPCR of OAS1 mRNA 72 h post transduction.
689 IFN- β (1000 U/mL, 16 h) and cGAMP (10 μ g/ml, 16 h) served as positive controls. Bars represent
690 mean of $n = 3-6 \pm$ SEM (biological replicates). Lower panel: Corresponding immunoblots of
691 WCLs stained by anti-FLAG, anti-STING and anti-GAPDH. **i**, Impact of supernatant (SN) from
692 primary fibroblasts from healthy donors (n1, f1) or a patient (Patient 1) on ISRE promoter activity
693 in 293-Dual-hSTING-R232 cells. IFN- β (100 U/mL, 48 h) and cGAMP (10 μ g/ml, 48 h) served
694 as positive controls. SEAP activity was quantified 48 h post SN transfer and normalised to cell
695 viability. Bars represent mean of $n = 3 \pm$ SEM (biological replicates).

696

697 **Figure 3: ARF1 R99C disrupts mitochondria, releasing mtDNA into the cytoplasm. a,**
698 Induction of the ISRE promoter in THP-1-Dual WT (grey) and THP-1-Dual KO-cGAS (pink) cells
699 transduced with lentiviral vectors expressing ARF1 WT or R99C as indicated, quantified by Lucia
700 luciferase (LLuc) activity 72 h post transduction. IFN- β (1000 U/mL, 16 h) and cGAMP (10 μ g/ml,
701 16 h) served as positive controls. Bars represent mean of $n=3 \pm$ SEM (biological replicates). Lower
702 panel: Corresponding immunoblots of WCLs stained by anti-FLAG, anti-STING, anti-cGAS and
703 anti-GAPDH. **b**, Exemplary electron microscopy analysis of HEK293T cells transiently
704 transfected with ARF1 WT or ARF1 R99C as indicated. Mitochondria (m) are highlighted in insets
705 in bottom panels. Electron-dense granules and inflated cristae are highlighted by black and white
706 arrows, respectively. Annotations: cp, cytoplasm; er, endoplasmic reticulum; g, Golgi apparatus;
707 lv, large vesicle; ly, lysosome; m, mitochondria; nc, nucleus. **c**, Exemplary immunoblots showing
708 fractionation of ARF1 WT, R99C, Q71L and vector transfected HEK293T cells as indicated.
709 WCLs and fraction blots stained by anti-FLAG, anti-TFAM (mitochondria), anti-LAMIN B1
710 (nucleus) and anti-GAPDH (cytosol). **d**, qPCR of mtDNA (MT-D-Loop) in the cytosolic fraction
711 of (c) relative to total normalized cellular mtDNA (mtDNA/nuclear DNA) using the $\Delta\Delta CT$

712 method. $n = 3 \pm \text{SEM}$. **e**, qPCR of mtDNA (MT-D-Loop) in the cytosolic fraction of primary
713 fibroblasts from healthy donors (n2, f1, I7) or a patient (Patient 1) relative to total normalized
714 cellular mtDNA (mtDNA/nuclear DNA) using the $\Delta\Delta\text{CT}$ method. $n = 5 \pm \text{SEM}$. **f**, qPCR of
715 representative ISG *OAS1* in U2OS cells stably expressing STING and depleted of mtDNA by ddC,
716 or untreated (NT), upon transfection with empty vector, ARF1 WT or R99C $n=3 \pm \text{SEM}$. **g**,
717 Exemplary immunoblot of WCLs of HEK293T cells transiently expressing ARF1 WT, R99C or
718 vector. Blots were stained with anti-MFN1, anti-RHOT1, anti-FLAG and anti-GAPDH.
719 Quantification of the band intensities for MFN1 normalized to the band intensities of GAPDH.
720 Bars represent mean of $n = 6 \pm \text{SEM}$ (biological replicates). **h**, Exemplary immunoblots showing
721 fractionation of HEK293T cells expressing ARF1 WT, R99C or vector control as well as VCP.
722 WCLs and fraction blots stained by anti-FLAG, anti-HA, anti-TFAM (mitochondria), anti-
723 LAMIN B1 (nucleus) and anti-GAPDH (cytosol). **i**, qPCR of mtDNA (MT-D-Loop) in the
724 cytosolic fraction of (**h**) relative to total normalized cellular mtDNA (mtDNA/nuclear DNA) using
725 the $\Delta\Delta\text{CT}$ method. $n = 5 \pm \text{SEM}$.

726

727 **Figure 4. GTPase activity of ARF1 R99C is reduced.** **a**, Model of ARF1 (PDB: 2J59) in ATP-
728 bound form. R99 and D26 are highlighted. Phosphates in orange. **b**, Interaction of ARF1 WT with
729 GTP analysed by fluorescence thermal shift assay. **c**, Protein stability of ARF1 R99C and its
730 interaction with GTP analysed by fluorescence thermal shift assay. Data are representative of two
731 biological replicates. **d**, GTPase activity quantified by GTPase Glo assay of indicated ARF1
732 mutants purified from HEK293T cells expressing FLAG-ARF1 WT and mutants. Lower panel:
733 Corresponding immunoblot (one representative) stained with anti-FLAG displaying input
734 amounts. Bars represent mean of $n = 4 \pm \text{SEM}$ (biological replicates). **e**, Impact of expression of
735 ARF1 WT and R99C co-expressed with indicated GEF or GAP on ISRE promoter activity in 293-

736 Dual-hSTING-R232 reporter cells quantified by SEAP activity normalized to cell viability.
737 Corresponding immunoblots of WCLs were stained with anti-HA, anti-turboGFP (tGFP), anti-
738 FLAG, anti-STING and anti-GAPDH. Bars represent mean of $n = 3 \pm \text{SEM}$ (biological replicates).
739 **f**, Fold changes (log 10) of protein abundance in ARF1 WT versus R99C large scale purification
740 from HEK293T cells. Co-purifying proteins were assessed by SILAC mass spectrometry.
741 Components of the COPI machinery are highlighted in pink and annotated. **g**, Gene Ontology
742 Analysis (PantherDB) of the top 100 downregulated genes as determined in (f). Fold enrichment
743 of individual GO terms versus the $-\log P$ value is shown. FACT complex (GO:0035101), MCM
744 complex (GO:0042555), CMG complex (GO:0071162), COPI vesicle coat (GO:0030126), DNA
745 replication preinitiation complex (GO:0031261), chaperonin-containing T-complex
746 (GO:0005832), eukaryotic translation initiation factor 3 complex, eIF3m (GO:0071541), COPI-
747 coated vesicle membrane (GO:0030663), methylosome (GO:0034709), COPI-coated vesicle
748 (GO:0030137). Colour highlights the top 10 GO terms; orange, non-COPI terms; pink, COPI-
749 related GO terms.

750

751 **Figure 5: ARF1 is responsible for retrograde transport from the Golgi/ERGIC to the ER. a**,
752 Impact of FLAG-tagged ARF1 WT or R99C expression by transient transfection on ISRE
753 promoter activity in 293-Dual-hSTING-R232 cells either mock treated or treated with cGAMP
754 (1.25 $\mu\text{g/ml}$, 5 $\mu\text{g/ml}$; 16 h). SEAP activity was quantified 32 h post transfection and normalized
755 to cell viability. Bars represent mean of $n = 3 \pm \text{SEM}$ (biological replicates). Lower panel:
756 representative corresponding immunoblot stained with anti-FLAG, anti-STING and anti-GAPDH.
757 **b**, Area under the curve analysis of the data in (a). **c**, Type I IFN signalling activation by expression
758 of ARF1 WT and R99C in the presence of indicated STING mutants in HEK93T cells, assessed
759 by ISRE-promoter firefly luciferase reporter gene assay 32 h post transfection, normalised to

760 GAPDH-promoter driven Renilla luciferase. Bars represent mean of $n = 3 \pm \text{SEM}$ (biological
761 replicates). **d**, Representative electron microscopic images of HEK293T cells expressing the
762 indicated ARF1 mutants. Exemplary electron microscopic images with (bottom) and without (top)
763 highlighted luminal area are shown. Scale bar, $0.5 \mu\text{m}$ **e**, Golgi/ERGIC luminal volume and **f**,
764 associated vesicle volume quantified in tomograms of cells in (**d**), as assessed as percentage of the
765 total volume of the analysed section. Bars represent mean of $n = 9 \pm \text{SEM}$ (images). **g**,
766 Quantification of particles of ERGIC-53 staining (left panel), particle size (middle panel) or the
767 total are (right panel), in HeLa cells transiently expressing ARF1 WT, R99C, Q71L or T31N. Cells
768 were stained 24 h post transfection with anti-ERGIC-53 and anti-FLAG. Black lines represent
769 mean of $n = 39-61 \pm \text{SEM}$ (individual cells). **h**, Pearson's correlation coefficient indicating the co-
770 localisation between GM130 and thermosensitive VSV-G (VSVG-ts045) in HeLa cells transfected
771 with VSVG-ts045-KDEL and vector control, ARF1 WT or ARF1 R99C. Cells were incubated
772 at 37°C for 24 h, then either fixed or further incubated at 32°C for 2 h and then either fixed or
773 shifted to 40°C for 1 h and fixed. Temperature shifts ($37^\circ\text{C}/32^\circ\text{C}/40^\circ\text{C}$) as indicated. Lines
774 represent mean of $n = 14-29 \pm \text{SEM}$ (cells).

775

776 **Figure 6: STING accumulates at the ERGIC in the presence of ARF1 R99C.** **a**, Exemplary
777 confocal laser scanning microscopy images of STING-eGFP (green) and indicated FLAG-tagged
778 ARF1 mutants in HeLa cells. Details are shown as higher magnification insets. Cells were stained
779 24 h post transfection with anti-FLAG (red) and anti-GM130 (grey). Nuclei, DAPI (blue). Scale
780 bar, $10 \mu\text{m}$. **b**, Quantification of the co-localisation of ARF1 and GM130 and **c**, STING and
781 GM130 from the images shown in (**a**), using Pearson's correlation coefficient. Lines represent
782 mean of $n = 19-26 \pm \text{SEM}$ (individual cells). **d**, Exemplary confocal laser scanning microscopy
783 images and respective high-magnification insets of primary fibroblasts from a healthy donor or

784 patient 1. The cells were either mock treated or treated with cGAMP (10 μ g/ml, 3 h) and stained
785 with anti-STING (green) and anti-GM130 (grey). Nuclei, DAPI (blue). Scale bar, 10 μ m. **e**,
786 Quantification of the co-localisation of STING and GM130 from the images shown in (**d**), using
787 Pearson's correlation coefficient. Lines represent mean of $n = 60-65 \pm$ SEM (individual cells). **f**,
788 Exemplary STED super-resolution microscopy images and respective high-magnification insets
789 of NHLF cells transduced with lentiviruses expressing indicated ARF1 constructs or empty vector.
790 48 h post transduction the cells were stained with anti-STING (green), anti-FLAG (not shown) and
791 anti-GM130 (red). Only FLAG-staining positive cells are displayed. Scale bar, 10 μ m. **g**, Presence
792 and localisation of pTBK1 (green) in relation to ARF1 (FLAG; red) and ERGIC53 (white) in
793 NHLF cells transduced with lentiviruses expressing indicated ARF1 constructs or empty vector.
794 Details are shown as higher magnification insets. cGAMP (10 μ g/ml, 3 h) was used as positive
795 control. Scale bar, 5 μ m. **h**, Quantification of the area (in pixels) of pTBK1 puncta observed in (**g**).
796 Lines represent mean of $n = 57-96 \pm$ SEM (individual cells).

797

798 **MATERIALS AND METHODS**

799 **Cell culture.** HEK293T (ATCC), HEK293T ATG5 KO, Hela (ATCC), 293-Dual-hSTING-R232
800 (Invivogen), A549-Dual (Invivogen) cell lines, normal human lung fibroblast primary cells
801 (Lonza) and normal human dermal fibroblasts primary cells (Thermo Fisher, Innoprot and
802 Promocell) were cultivated in Dulbecco's Modified Eagle Medium (DMEM) supplemented with
803 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin, 100 μ g/ml streptomycin, and 2 mM L-
804 glutamine. THP-1-Dual and THP-1-Dual KO-cGAS (both Invivogen) cells were cultivated in
805 RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin,
806 100 μ g/ml streptomycin, and 2 mM L-glutamine. U2OS cells (ATCC) were maintained in McCoy

807 medium (Invitrogen) supplemented with 10% (v/v) fetal bovine serum. All cells were incubated at
808 37°C in a 5% CO₂, 90% humidity atmosphere. Patient cells are from Patient 1 were isolated by
809 skin punch biopsy and cultivated as the other dermal fibroblast cells.

810 **Ethics.** Clinical information and samples were obtained with informed consent. The study
811 was approved by the Comité de Protection des Personnes (ID-RCB/EUDRACT: 2014-A01017-
812 40) in France, and the Leeds (East) Research Ethics Committee (REC reference:
813 10/H1307/2 IRAS project ID: 62971) in the UK. ARF1 patient cells were handled with approval
814 of the Ethics Committee at Ulm University (Approval 530/21).

815 **Expression constructs and cloning.** A construct coding for human ARF1 (pCMV6-hARF1-myc-
816 FLAG) was purchased from Origene (kindly provided by Michaela Gack, Florida). Mutations in
817 R99C, Q71L and T31N were introduced by Q5 site-specific mutagenesis (see primers in table 1).
818 Constructs coding for cGAS 3×-FLAG and STING-FLAG were kindly provided by Jae U. Jung
819 (University of Southern California). STING-FLAG mutations R238A/Y240A and S366A were
820 introduced by Q5 site-specific mutagenesis (see primers in table 1). pEGFP-VSVG was a gift from
821 Jennifer Lippincott-Schwartz (Addgene plasmid # 11912⁶⁰). ECFP-ELP1-25 was a gift from
822 Michael Davidson (Addgene plasmid # 55341). The open reading frame (ORF) of KDELR (ELP1)
823 was subcloned into the pEGFP-VSVG vector using Gibson assembly (New England Biolabs). The
824 insert was amplified by PCR (see primers in table 1) and the vector linearized with EcoRI and
825 ApaI restriction enzymes (New England Biolabs). The ORF of TagRFP (from pCR3-TagRFP) was
826 subcloned into the pCMV6-hARF1-myc-FLAG vector and the pCMV6-hARF1-R99C-myc-
827 FLAG vector using Gibson assembly. The insert was amplified by PCR (see primers in table 1)
828 and the vectors were linearized with MluI and PmeI restriction enzymes (New England Biolabs).
829 To insert the ORFs of ARF1 WT or ARF1 R99C (from pCMV6-ARF1, Origene) in a lentiviral
830 backbone, both ORFs together with IRES-Puro (from pIRES-TRIM2-FLAG) were subcloned into

831 the pBoB-hCas9-IRES-Bla vector using Gibson assembly. The inserts were amplified by PCR (see
 832 primers in table 1) and the vector was linearized with XbaI and PmeI restriction enzymes (New
 833 England Biolabs). Constructs coding for human ARFGAP1 (pCMV3-ARFGAP1-HA)) and VCP
 834 (pCMV3-VCP-HA) were purchased from Sino Biologicals. pGAPDH_PROM_01_Renilla SP
 835 Luciferase and pISRE-FLuc plasmids were described previously⁶¹. Human STING ORF was
 836 amplified from pMSCV-hygro-STING plasmid (Addgene #102598) by PCR (see primers in table
 837 1) and inserted into linearized pEGFP-C3 (Clontech) using XhoI and EcoRI enzymes (New
 838 England Biolabs). pCMV6-ARFGEF1-TurboGFP was purchased from Clinisciences
 839 (RG222817).

840 **Table 1: Primers used for cloning.**

Name	Sequence 5' – 3'
ARF1-Q71Lfwd	TTG GAC AAG ATC CGG CCC CTG TGG
ARF1-Q71Lrev	GCC ACC CAC GTC CCA CAC AGT
ARF1-T31N-fwd	AAT ACG ATC CTC TAC AAG CTT AAG CTG GGT GAG A
ARF1-T31N-rev	CTT CCC TGC AGC ATC CAG GCC
ARF1 R99Cfwd	GAG TGT GTG AAC GAG GCC CGT GAG GAG C
ARF1 R99Crev	TCT GTC ATT GCT GTC CAC CAC GAA GAT C
STING-R238A/Y240A- fwd	CAT CAA GGA TGC GGT TGC CAG CAA CAG CAT C
STING-R238A/Y240A- rev	CCA GCA CGG TCA GCG GTC TG
STING-S366A-fwd	GCT CCT CAT CGC TGG AAT GGA AAA GCC C

STING-S366A-rev	TCA GGC TCT TGG GAC ATC
VSVG(tsO45)-KDELRFwd	GAC TTG GAA ACA GAA TTC TGA TGG CCA TGA ACA TTT TCC G
VSVG(tsO45)-KDELRFrev	CTC ACC ATT GGA TCC CGG GCC CCT GCT GGC AAA CTG AGC TTC T
ARF1-TagRFP-fwd	GTC CAA TCA GCT CCG GAA CCA GAA GGC GGT GTC TAA GGG CGA AG
ARF1-TaqRFP-rev	CAG CTA TGA CCG CGG CCG GCC GT T TTT AAT TAA GTT TGT GCC CC
pBOB-ARF1-fwd	CCT CCA TAG AAG ACA CCG ACT CTA GAG CCA CCA TGG GGA ACA TCT TCG CC
pBOB-ARF1-rev	CTA TGA CCG CGG CCG GCC GTT TAA ACC TTA TCG TCG TCA TCC
pBOB-IRES-Puro-fwd	ACG GCC GGC CGC GGT CAT AGG CGG CCG CTC TAG CCC AAT TCC
pBOB-IRES-Puro-rev	GCT CCA TGT TTT TCC AGG TTT TCA GGC ACC GGG CTT GCG
EGFP-STING-fwd	ATT ACT CGA GAT GCC CCA CTC CAG
EGFP-STING-rev	GAA TTC TCA AGA GAA ATC CGT GCG GA

841

842 **Transfection of mammalian cells.** DNA of expression vectors was transiently transfected using
843 either the TransIT-LT1 Transfection Reagent (Mirus) or Polyethylenimine (PEI, 1 mg/ml in H₂O)
844 according to the manufacturers recommendations or as described previously⁶².

845 **Transduction of mammalian cells.** pMDLg, RSV-Rev, and pMD.G together with the generated
846 pBOB constructs were used to rescue 3rd generation lentiviruses as previously described^{61,62}. Cells
847 were incubated with 3rd generation lentiviral particles for 16 h. Subsequently, the cells were
848 washed three times with DMEM and incubated for further 48 h.

849 **Whole-cell lysates.** Whole-cell lysates were prepared by harvesting cells in Phosphate-Buffered
850 Saline (PBS, Gibco). If not mentioned otherwise, the cell pellet (500 g, 4 °C, 5 min) was lysed as
851 previously described⁶² in transmembrane lysis buffer (150 mM NaCl, 50 mM 4-(2-hydroxyethyl)-
852 1-piperazineethanesulfonic acid (HEPES) pH 7.4, 1% Triton X-100, 5 mM
853 ethylenediaminetetraacetic acid (EDTA)) by vortexing at maximum speed for 30 s. Cell debris
854 was removed by centrifugation (20,000 g, 4 °C, 20 min), and the protein concentration of the
855 supernatants was quantified using a BCA assay (Pierce Rapid Gold BCA Protein Assay Kit,
856 Thermo Fisher Scientific). The lysates were then stored until analysis at -20 °C.

857 **SDS-PAGE and Immunoblotting.** SDS-PAGE and immunoblotting was performed using
858 standard techniques as previously described⁶². In brief, whole cell lysates were mixed with 6x
859 Protein Sample Loading Buffer (LI-COR, at a final dilution of 1x) supplemented with 15% β-
860 mercaptoethanol, heated to 95°C for 5 min, separated on NuPAGE 4-12% Bis-Tris Gels
861 (Invitrogen) for 90 minutes at 90 V and blotted onto Immobilon-FL PVDF membranes (Merck
862 Millipore). The transfer was performed at a constant voltage of 30 V for 30 min. After the transfer,
863 the membrane was blocked in 1% Casein in PBS. Proteins were stained with primary antibodies
864 mouse anti-FLAG M2 (1:5000, Sigma-Aldrich), sheep anti-STING (1:1000, Bio-Techne), rabbit
865 anti-pTBK1 (1:1000, Cell Signaling), rabbit anti-TBK1 (1:1000, Cell Signaling), rabbit anti-IRF3
866 (1:1000, Cell Signaling), rabbit anti-HA (1:1000, Cell Signaling), rabbit anti-ARF1 (1:300,
867 Proteintech), rabbit anti-cGAS (1:2000, Proteintech), rabbit anti-RFP (1:1000, Abcam), mouse
868 anti-turboGFP (1:1000, Origene), rabbit anti-TFAM (1:1000, Proteintech), mouse anti-Lamin B1

869 (1:10,000, Proteintech), rat anti-GAPDH (1:1000, BioLegend), rabbit anti-MFN1 (1:1000, Cell
870 Signaling), mouse anti-RHOT1 (1:1000, Abnova), mouse anti-Drp1 (1:1000, Cell Signaling),
871 rabbit anti-pDrp1 (1:1000, Cell Signaling), rabbit anti-SURF4 (1:1000, Novus Biologicals) and
872 subsequently Infrared Dye labelled secondary antibodies (LI-COR), diluted in 0.05% Casein in
873 PBS. Band intensities were quantified using Image Studio lite (LI-COR).

874 **Luciferase reporter assays.** Luciferase reporter assays were performed as previously described
875 in detail⁶³. In brief, HEK293T cells were either transiently transfected with luciferase reporter
876 constructs, or reporter cell lines (A549-Dual, 293-Dual hSTING-R232, THP-1-Dual or THP1-
877 Dual KO-cGAS) were used. 32 h post- transfection or 72 h post transduction, cells were lysed in
878 passive lysis buffer (Promega) and luciferase activities of the firefly luciferase (FFLuc), renilla
879 luciferase, lucia luciferase or SEAP activity were determined. For HEK293T cells ISRE-firefly
880 luciferase activities normalised to renilla activity were measured via DualGlo Luciferase Assay
881 System (Promega). For the reporter cell lines ISRE-lucia luciferase activity (IFN β -lucia luciferase
882 for 293-Dual hSTING-R232 cells) was measured 1 s after injecting 20 mM coelenterazine (PFK
883 Biotech) and NF- κ B-SEAP activity (ISRE-SEAP for 293-Dual hSTING-R232 cells) via Alkaline
884 Phosphatase Blue Microwell Substrate (Sigma-Aldrich). Both were normalized to cell viability
885 determined by the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luciferase and cell
886 viability measurements were performed using an Orion II microplate Luminometer (Berthold),
887 SEAP activity was measured at 650 nm by using a Vmax kinetic microplate reader (Molecular
888 Devices) and the SoftMax Pro 7.0.3 software.

889 **Generation of U2OS cells stably expressing STING and mtDNA depletion.** The pMSCV-hygro
890 plasmid carrying WT STING1 cDNA (Addgene plasmid #102598) or empty vector were used in
891 combination with packaging vector pCL-Ampho (Novus) and envelope vector pCMV-VSV-G
892 (Addgene plasmid #8454) to produce retroviral vectors as described for lentiviral vectors. 100,000

893 U2OS cells were transduced with 0.5 mL retroviral vectors, 8 $\mu\text{g}/\text{mL}$ polybrene (Millipore) and
894 10 mM HEPES (Invitrogen) in 12-well plates, and medium replaced 24 hours later. Two days after
895 transduction, transduced cells were selected and maintained in culture with 200 $\mu\text{g}/\text{mL}$
896 hygromycin B (Invivogen). STING expression was verified by western blotting. mtDNA depletion
897 in U2OS and U2OS-STING cells was induced by 100 μM 2',3' dideoxycytidine (ddC, Sigma-
898 Aldrich) treatment in medium supplemented with 50 $\mu\text{g}/\text{mL}$ uridine (Sigma-Aldrich) and 1 mM
899 sodium pyruvate (GIBCO) for seven to fourteen days before use. To control for mtDNA depletion,
900 total DNA from 500,000 cells was extracted using the DNeasy Blood and Tissue Kit (Qiagen),
901 following the manufacturer's instructions. DNA concentrations were determined by photometry
902 (Nanodrop) and 15 ng and 7.5 ng DNA were used to perform qPCR for the mitochondrial gene
903 MT-COXII and the nuclear gene GAPDH (see primers in Table 3). Quantitative PCR (qPCR) was
904 performed using Power SYBR Green (Invitrogen). Ratios of $\Delta\Delta\text{Ct}$ for MT-COXII over GAPDH
905 for the different DNA concentrations were averaged and the fold change to untreated (UT) is
906 shown in figures. U2OS cells were stimulated for 4 hours with 2 $\mu\text{g}/\text{mL}$ HT-DNA (Sigma-Aldrich)
907 complexed with Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions, or
908 lipofectamine alone.

909 **Generation of HEK293T ATG5 KO cells.** HEK293T ATG5 KO cells were generated by
910 genomic knock out using CRISPR Cas9. To this end, 3rd generation lentiviral vectors were
911 generated as described before⁶² using pSicoR-CRISPR-PuroR CRISPR/Cas9⁶⁴ constructs
912 harboring an ATG5 targeting sgRNA or a non-targeting (NT) sgRNA. (NT:
913 ACGGAGGCTAAGCGTCGCAA, ATG5: AACTTGTTTCACGCTATATC)⁶⁵ as the transfer
914 plasmid. HEK293T cells were transduced with the lentiviral vectors and 3 days post-transduction
915 separated into individual cells using limited dilution. The individual cells were grown into clonal
916 cell lines and screened for ATG5 KO using Western blot analysis (anti-ATG5 antibody, Cell

917 Signaling Technology, #2630). Clones with a conformed knock out were expanded and stocks
918 were conserved by cryo preservation.

919 **Overexpression of WT and mutant ARF1 in U2OS cells.** U2OS WT and U2OS-STING cells
920 plated in 12-well plates were transiently transfected with ARF1 WT, ARF1 R99C or empty vector.
921 Cells were collected 24 hours later for RNA and protein analysis. Total RNA was extracted using
922 the RNAqueous-Micro Kit (Ambion), and reverse transcription performed with the High-Capacity
923 cDNA Reverse Transcription Kit (Applied Biosystems). Levels of cDNA were quantified by RT-
924 qPCR using TaqMan Gene Expression Assay (Applied Biosystems). Differences in cDNA inputs
925 were corrected by normalization to HPRT1 cDNA levels. Relative quantitation of target cDNA
926 was determined by the formula $2^{-\Delta\Delta CT}$ (See Taqman probes in table 4). For whole cell lysate
927 analysis, proteins were extracted from U2OS cells using RIPA lysis buffer with 1% protease
928 inhibitor and 1% phosphatase inhibitor. Bolt LDS Sample Buffer (4X, Novex Life Technologies)
929 and Bolt Sample Reducing agent (10X, Novex Life Technologies) were added to protein lysates,
930 samples resolved on 4-12 % Bis-Tris Plus NuPAGE gels (Invitrogen) and then transferred to
931 nitrocellulose membrane for 7 min at 20 V using the iBlot 2 Dry Blotting System (Invitrogen). To
932 analyse protein phosphorylation status, membranes were blocked in LI-COR buffer, and primary
933 phospho-antibodies (rabbit anti-pIRF3, 1:1000; rabbit anti-pSTING, 1:1000, Cell Signaling)
934 incubated for 48 hours in blocking solution. For cofilin immunoblot, membranes were blocked
935 with 5% non-fat milk in TBS, and primary antibodies (rabbit anti-Cofilin, 1:1000, Cell Signaling)
936 incubated overnight at 4°C in 1.5% Bovine Serum Albumin in TBS buffer supplemented with
937 0.1% Tween. After stripping, membranes were reblotted with anti-STING antibodies (mouse anti-
938 STING, 1:1000, R&D Systems; rabbit anti-IRF3, 1:1000, Cell Signalling) in 2.5% non-fat milk in
939 TBS buffer supplemented with 0.1% Tween. After washing, membranes were incubated with
940 appropriate anti-mouse or anti-rabbit secondary antibodies for 45 minutes at room temperature

941 (LI-COR). Signal was detected using the OdysseyCLx System (LI-COR). Comparative signal
942 analyses were performed using Fiji (ImageJ).

943 **Assessing mitochondrial DNA release into the cytosol.** HEK293T WT or HEK293T ATG5 KO
944 cells were transfected with ARF1 WT, ARF1 R99C or empty vector. Alternatively, HEK293T WT
945 cells were transfected with ARF1 WT, ARF1 R99C or empty together with VCP or empty vector.
946 24 h later, cells were treated with 10 μ M of ABT-737 and 10 μ M Quinoline-Val-Asp-
947 Difluorophenoxymethylketone (Q-VD-OPH) as a positive control. In the case of primary human
948 dermal fibroblasts, cells from four healthy donors or from patient 1 were used. On the next day,
949 the cells were harvested and isolation and quantification of DNA from cytosolic, mitochondrial
950 and nuclear fractions was performed as described previously⁶⁶ (basic protocol 2). Briefly, half of
951 the cells were lysed in SDS lysis buffer (20 mM Tris, pH 8, 1% (v/v) SDS, protease inhibitors) to
952 obtain WCLs for normalisation, whereas the other half was used for fractionation. Cytosolic,
953 mitochondrial and nuclear extracts were isolated by subsequently incubating the cells with saponin
954 lysis buffer (1x PBS, pH 7.4, 0.05% saponin, protease inhibitors), NP-40 lysis buffer (50 mM
955 Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 10% (v/v) glycerol, protease
956 inhibitors) and SDS lysis buffer (20 mM Tris, pH 8, 1% (v/v) SDS, protease inhibitors),
957 respectively. Purity of the fractions was determined by immunoblotting for GAPDH (cytosolic
958 extract), TFAM (mitochondrial extract), and Lamin B1 (nuclear extract). DNA extraction of the
959 fractions and WCLs was performed using phenol-chloroform. DNA concentrations were
960 determined by photometry (Nanodrop) and equal amounts of DNA were used to perform qPCR
961 for mitochondrial DNA (MT-Dloop) and nuclear DNA (KCNJ10) (see primers in Table 3). qPCR
962 was performed using PowerUP SYBR Green (Applied Biosystems) and the relative cytosolic
963 mtDNA was calculated using the $\Delta\Delta$ CT method.

964 **Table 3: Primers used for SYBR Green qPCR.**

Type	Primers	Sequence
SYBR Green	MT-COXII_F	CGTCTGAACTATCCTGCCCCG
SYBR Green	MT-COXII_R	TGGTAAGGGAGGGATCGTTG
SYBR Green	GAPDH_F	ATGCTGCATTCGCCCTCTTA
SYBR Green	GAPDH_R	GCGCCCAATACGACCAAATC
SYBR Green	KCNJ10 fwd	GCGCAAAGCCTCCTCATT
SYBR Green	KCNJ10 rev	CCTTCCTTGGTTTGGTGGG
SYBR Green	MT-Dloop fwd	CATAAAGCCTAAATAGCCCACACG
SYBR Green	MT-Dloop rev	CCGTGAGTGGTTAATAGGGTGATA

965

966 **Expression of WT and mutant ARF1 in NHLF cells.** NHLF cells were transduced with lentiviral
967 particles coding for ARF1 WT, ARF1 R99C or empty vector. For qPCR analysis, total RNA was
968 extracted 72 h post transduction using the Quick-RNA Microprep Kit (Zymo research) according
969 to the manufacturer's instructions. Reverse transcription and qRT-PCR were performed in one
970 step using the SuperScript III Platinum Kit (Thermo Fisher Scientific) on a StepOnePlus Real-
971 Time PCR System (Applied Biosystems) according to the manufacturer's instructions. TaqMan
972 probes for each individual gene were acquired as premixed TaqMan Gene Expression Assays
973 (Thermo Fisher Scientific) and added to the reaction (See probes in table 4). Expression levels for
974 each target gene were calculated, e.g. for OAS1 expression levels by normalizing to GAPDH
975 cDNA levels using the $\Delta\Delta CT$ method.

976

977 **Table 4: Primers used for TaqMan qPCR.**

Type	Primers	Assay ID
TaqMan	HPRT1	Hs03929096_g1

TaqMan	IFI27	Hs01086370_m1
TaqMan	RSAD2	Hs01057264_m1
TaqMan	OAS1	Hs00973637_m1
TaqMan	MX1	Hs00895608_m1
TaqMan	IFNB1	Hs01077958_s1

978

979 **Dimerization assay.** HEK293T cells were transfected with ARF1 WT (pCMV6-ARF1-myc-
980 FLAG or pCMV6-ARF1-Tag-RFP, or with pCMV6-ARF1-myc-FLAG and pCMV6-ARF1-Tag-
981 RFP) or ARF1 R99C (pCMV6-ARF1-R99C-myc-FLAG or pCMV6-ARF1-R99C-Tag-RFP, or
982 with pCMV6-ARF1-R99C-myc-FLAG and pCMV6-ARF1-R99C-Tag-RFP). 24 h post
983 transfection, WCLs were prepared and input samples were saved for western blotting. The WCLs
984 were incubated with anti-FLAG M2 magnetic beads (Sigma-Aldrich) for 4 h at 4 °C on a rotating
985 shaker. Subsequently, the beads were washed five times with transmembrane lysis buffer and
986 incubated with 1x Protein Sample Loading Buffer supplemented with 15% β -mercaptoethanol.
987 After heating to 95°C for 10 min the samples were applied to SDS-PAGE and immunoblotting.

988 ***In vitro* GTPase assays.** HEK293T cells were transfected with pCMV6-ARF1-myc-FLAG,
989 pCMV6-ARF1-R99C-myc-FLAG, pCMV6-ARF1-Q71L-myc-FLAG or pCMV6-ARF1-T31N-
990 myc-FLAG. 24 h later, WCLs were prepared in GTPase lysis buffer (150 mM NaCl, 50 mM
991 HEPES pH 7.4, 1% Triton X-100, 5 mM MgCl₂, 5 mM EDTA) and incubated with anti-FLAG
992 M2 magnetic beads (Sigma-Aldrich) for 4 h at 4 °C on a rotating shaker. Subsequently, the beads
993 were washed three times with washing buffer I (500 mM NaCl, 50 mM HEPES pH 7.4, 1% Triton
994 X-100, 5 mM MgCl₂, 5 mM EDTA) and twice with washing buffer II (100 mM NaCl, 50 mM
995 HEPES pH 7.4, 1% Triton X-100, 5 mM MgCl₂, 5 mM EDTA). Next, the beads were incubated
996 with GTPase-Glo-GEF assay buffer (Promega) and the GTPase reaction was performed according

997 to the manufacturer's recommendations (GTPase-Glo assay, Promega). In short, the beads were
998 incubated with 2x GTP solution for 16 h followed by the addition of the GTPase-Glo reagent and
999 the detection reagent. The resulting luminescence was measured using an Orion II microplate
1000 Luminometer (Berthold).

1001 **Stable isotope labelling of amino acids in cell culture (SILAC).** To analyse interaction partners
1002 of ARF1 WT and ARF1 R99C, stable isotope labelling of amino acids in cell culture (SILAC)-
1003 based quantitative mass spectrometry (MS) was performed. HEK293T cells were cultivated in
1004 SILAC medium light (DMEM for SILAC supplemented with 10% (v/v) dialyzed FBS, 100 U/ml
1005 penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 200 mg/ml proline, 84 mg/ml L-arginine,
1006 146 mg/ml L-lysine) or SILAC medium heavy (DMEM for SILAC supplemented with 10% (v/v)
1007 dialyzed FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 200 mg/ml
1008 proline, 87.2 mg/ml ¹³C¹⁵N-labelled L-arginine, 152.8 mg/ml ¹³C¹⁵N-labelled L-lysine) for five
1009 passages to completely incorporate the labelled amino acids. Afterwards, the cells were either
1010 transfected with ARF1 WT (heavy) or ARF1 R99C (light). 24 h later, WCLs were prepared from
1011 1x10⁷ cells and incubated with anti-FLAG M2 magnetic beads (Sigma-Aldrich) for 4 h at 4 °C on
1012 a rotating shaker. Subsequently, the beads were washed five times with transmembrane lysis buffer
1013 and incubated with 1x Protein Sample Loading Buffer supplemented with 15% β-mercaptoethanol.
1014 After heating to 95°C for 10 min the samples were applied to SDS-PAGE and immunoblotting or
1015 MS.

1016 **Mass spectrometry (MS) and data analysis.** SILAC labelled samples were combined in a 1-to-
1017 1 manner and proteins were separated using standard 12.5% SDS-Page followed by colloidal
1018 Coomassie staining and subsequent sample preparation as described earlier⁶⁷. Samples were
1019 measured using an LTQ Orbitrap Velos Pro system (Thermo Fisher Scientific) online coupled to
1020 an U3000 RSLCnano (Thermo Fisher Scientific) as described previously⁶⁷. Database search was

1021 performed using MaxQuant Ver. 1.6.3.4 (www.maxquant.org)⁶⁸. For peptide identification and
1022 quantitation, MS/MS spectra were correlated with the UniProt human reference proteome set
1023 (www.uniprot.org, Version on March 16th 2021), supplemented with the ARF1 sequences,
1024 employing the build-in Andromeda search engine ⁶⁹. The respective SILAC modifications and
1025 carbamidomethylated cysteine were considered as a fixed modification along with oxidation (M),
1026 and acetylated protein N-termini as variable modifications. False discovery rates were set on both,
1027 peptide and protein level, to 0.01. Subsequent data analysis was performed employing MS Excel
1028 and Origin Pro 2017G. For outlier analysis significance B was calculate using Perseus
1029 (<https://maxquant.org/perseus/>) and proteins with log2 rations were considered as regulated.

1030 **Go-Term Analysis.** The top 100 genes less associated with ARF1 R99C compared to ARF1 WT
1031 according to the SILAC experiment were submitted to PantherDB^{70,71}. Analysis Type: PANTHER
1032 Overrepresentation Test (Released 20220202). GO Ontology database DOI:
1033 10.5281/zenodo.6399963, Released 2022-03-22. Reference List:Homo sapiens (all genes in
1034 database).

1035 **Immunofluorescence.** Cells were seeded on coverslips (VWR) in 24-well plates and treated as
1036 indicated. Next, the samples were washed with PBS and fixed in 4% paraformaldehyde solution
1037 (PFA) for 20 min at RT, permeabilized and blocked with PBS containing 0.5 % Triton X-100 and
1038 5 % FCS for 1 h at RT. Afterwards, the cells were washed with PBS and incubated for 2 h at 4 °C
1039 with primary antibody (mouse anti-FLAG M2, 1:400, Sigma-Aldrich; rabbit anti-GM130, 1:400,
1040 Cell Signaling; rabbit anti-ERGIC-53, 1:400, Proteintech; sheep anti-TGN46, 1:400, Bio-Rad;
1041 rabbit anti-pTBK1, 1:100, Cell Signaling; mouse anti-STING, 1:100, Novus Biologicals, rabbit
1042 anti-STING, 1:200, Proteintech)) diluted in PBS with 1 % FCS. After washing with PBS/0.1 %
1043 Tween 20, the samples were incubated with the secondary antibody (donkey anti-mouse IgG
1044 (H+L) Alexa Fluor Plus 568, donkey anti-mouse IgG (H+L) Alexa Fluor Plus 488, donkey anti-

1045 rabbit IgG (H+L) Alexa Fluor Plus 647, donkey anti-sheep IgG (H+L) Alexa Fluor Plus 647,
1046 1:400, Thermo Fisher Scientific) or with primary antibody-secondary antibody conjugates (rabbit
1047 anti-ERGIC-53, 1.25 $\mu\text{g/ml}$, Proteintech; rabbit anti-GM130, 0.585 $\mu\text{g/ml}$, Cell Signaling; rabbit
1048 anti p-TBK1, 1.42 $\mu\text{g/ml}$, Cell Signaling; rabbit anti-STING, 3.5 $\mu\text{g/ml}$, Proteintech; mouse anti-
1049 FLAG M2 0.35 $\mu\text{g/ml}$, Sigma-Aldrich; conjugated to equal amounts ($\mu\text{g/ml}$) of Zenon Alexa Fluor
1050 647 rabbit IgG labelling reagent, Zenon Alexa Fluor 568 rabbit IgG labelling reagent, Zenon
1051 Alexa Fluor 488 rabbit IgG labelling reagent or Zenon Pacific Blue mouse IgG_{2a} labelling reagent,
1052 Thermo Fisher Scientific) and 500 ng/ml DAPI for 2 h at 4 °C in the dark. Next, the samples were
1053 washed with PBS/0.1 % Tween 20 and water and the cover slips were mounted onto microscopy
1054 slides. Images were acquired using a Zeiss LSM 710 confocal laser scanning microscope with
1055 ZEN imaging software (Zeiss). Images were analysed with ImageJ (Fiji). The number of ERGIC-
1056 53 positive particles and the particle size was analysed using a custom ImageJ macro (Fiji). Co-
1057 localization was determined with the Huygens Professional 19.04 software. In short, Pearson
1058 coefficients were calculated with the “Huygens Colocalization Analyzer” using the Costes
1059 method⁷² and applying individual thresholds.

1060 **Live cell imaging of mitochondria and Mitochondrial Network Analysis (MiNA).** HeLa cells
1061 were seeded in 35 mm μ -Dishes (Ibidi) and transfected with TagRFP-labelled ARF1 WT, ARF1
1062 R99C or vector control. 24 h later, all cells were treated with 1 μM Mitotracker and 1 $\mu\text{g/mL}$
1063 Hoechst 33342 for 30 min at 37°C. Sequentially the medium was removed and exchanged by fresh
1064 medium without phenol red. Images were then acquired using a Zeiss LSM 710 confocal laser
1065 scanning microscope with ZEN imaging software (Zeiss). Images analysis was performed with
1066 ImageJ (Fiji) using the the background subtractor tool (MOSAIC group) and the MiNA plugin
1067 (StuartLab). First, the background subtractor (length=20) was used, then the despeckle command
1068 and finally single cells were examined using the MiNA Analyse morphology plugin

1069 (threshold=moments)⁷³. The values obtained for the mitochondrial footprint (area/volume
1070 consumed by mitochondrial signal) were then used for visualization.

1071 **VSVG transport assay.** Retrograde transport of VSVG-ts045-KDEL_R was performed as
1072 described previously⁴³. In brief, HeLa cells were transfected with pEGFP-VSVG-ts045-KDEL_R
1073 and ARF1 WT, ARF1 R99C or empty vector. The cells were incubated at 37 °C for 24 h and then
1074 directly fixed or incubated at 32 °C for 2 h to accumulate the fusion protein at the Golgi complex.
1075 Cells were then either fixed or shifted to 40 °C for 1 h to allow one round of retrograde transport
1076 from the Golgi to the ER and then fixed.

1077 **STED sample preparation.** Normal human lung fibroblasts (NHLF; Lonza) were transduced with
1078 lentiviral particles coding for ARF1 WT, ARF1 R99C or empty vector. 48 h later, the samples
1079 were washed with PBS and fixed in 4% paraformaldehyde solution (PFA) for 20 min at RT. Next,
1080 the cells were permeabilized and unspecific binding was blocked by incubation with blocking
1081 solution (3% (w/v) BSA and 0.3% (v/v) Triton X-100 in PBS) for 2 h at RT. The samples were
1082 incubated overnight at 4°C with 1 µg/ml of the primary antibodies rabbit anti-GM130 (Cell
1083 Signaling) and mouse anti-STING (Novus Biologicals) dissolved in diluted blocking solution
1084 (0.3% (w/v) BSA and 0.03% (v/v) Triton X-100 in PBS). After three washing steps with PBS, the
1085 samples were incubated with 1 µg/ml secondary goat anti-mouse antibody conjugated with
1086 Atto647N (Sigma-Aldrich), 1 µg/ml goat anti-rabbit antibody conjugated with Atto594 (Sigma-
1087 Aldrich) and anti-rat antibody conjugated with Alexa Fluor Plus 405 (Thermo Fisher Scientific,
1088 transfection control) dissolved in diluted blocking solution (0.3% (w/v) BSA and 0.03% (v/v)
1089 Triton X-100 in PBS) for 1 h at RT. Unbound antibodies were removed in three washing steps
1090 with PBS. For imaging, samples were kept in 2,2'-thiodiethanol (97% TDE solution in PBS, pH
1091 7.5).

1092 **STED imaging.** Images were captured with a home-built dual-color 3D-STED microscope⁷⁴.
1093 Typically, an average power of $\sim 1 \mu\text{W}$ for each excitation beam (568 nm and 633 nm,
1094 respectively) and $\sim 1.5 \text{ mW}$ for each depletion beam (710 nm and 750 nm, respectively) was used.
1095 STED images were captured at a pixel size of 20 nm and a dwell time of 300 μs with a typical
1096 peak photon number of ~ 150 counts. Images were analyzed by ImageJ (Fiji). For better
1097 visualization, a Gaussian blur of $\sigma = 1$ was applied in each channel.

1098 **EM preparation.** Sample preparation was performed according to a standardized protocol⁷⁵.
1099 HEK293T cells were cultivated on UV-sterilized 160 μm thin carbon-coated sapphire disks
1100 (Engineering Office M.) and transfected with ARF1 WT, ARF1 R99C or empty vector. 24 h later,
1101 the samples were then cryo-fixed at a pressure of 230 MPa within 30 ms using a high-pressure
1102 freezer (HPF Compact 101). The samples were freeze substituted in a medium of acetone with
1103 0.1% uranyl acetate (UA), 0.2% osmium tetroxide (OsO_4), and 5% double distilled water for
1104 improved visibility of the membranes⁷⁶. Overnight (17h), samples were gradually warmed in an
1105 EM AFS2 (Leica Microsystems GmbH) freeze substitution device from -90 to $0 \text{ }^\circ\text{C}$. They were
1106 then left at $0 \text{ }^\circ\text{C}$ for 1 h and washed 3 times with acetone for 30 min each at room temperature and
1107 embedded in EPON resin (Sigma-Aldrich). For embedding, samples were incubated successively
1108 for one hour each in 33%, 50% and 67% EPON resin in acetone, then overnight in 100% EPON
1109 and polymerized for 48 h at $60 \text{ }^\circ\text{C}$. By plunging the solidified specimens in liquid nitrogen, the
1110 EPON block breaks in the region of the embedded sapphire discs leaving the cells on the surface
1111 ready to be sectioned with an ultramicrotome (Ultracut UC7, Leica Microsystems GmbH).

1112 **EM imaging.** For TEM imaging, 70 nm thin sections were mounted on carbon-coated Formvar
1113 films on copper grids (Plano GmbH) and imaged with a JEM-1400 TEM operating at 120 kV
1114 acceleration voltage equipped with a CCD camera (Veleta, Olympus Life Science). For STEM

1115 tomography, 800 nm thick sections were put on glow-discharged copper grids with parallel bars
1116 (Plano GmbH), pre-treated with 10% (w/v) poly-L-lysine (Sigma-Aldrich), followed by a second
1117 coating with poly-L-lysine to attach 25 nm colloidal gold particles (AURION Immuno Gold
1118 Reagents) on both sides of the cross-sections. A series of tilted images of the sections from an
1119 angle of -72° to $+72^\circ$ with an increment of 1.5° were recorded using a Jeol FEM 2100F field-
1120 emission TEM equipped with a Jeol STEM bright-field detector (Jeol Ltd) and , EM-Menu 4.0
1121 STEM tomography software (TVIPS) at a resolution of $1024 \text{ px} \times 1024 \text{ px}$, an illumination time
1122 of 20 s, and an acceleration voltage of 200 kV. Alignment of the images with the gold particles as
1123 fiducial markers as well as 3D-reconstruction of the tilt series was done as previously described⁷⁷
1124 using the IMOD 4.9 software⁷⁸.

1125 **EM stereology.** According to the Delesse principle, stating that the volume density of an organelle
1126 or component in a tissue can be estimated by measuring the area fraction of the intersections of
1127 the component within a random section of the tissue⁷⁹, volume fractions of luminal structures and
1128 small vesicles were determined by counting grid points on predefined classes within square test
1129 fields of $16 \mu\text{m}^2$ size using the recursive grid option implemented in the open-source software
1130 JMicroVision image analysis system. Since it is not possible to evaluate the entire cell, the
1131 precondition for stereological evaluation was that the section through the cell contained centrioles.
1132 The test fields were chosen so that the centrioles were located in their centre. This ensured that
1133 only similar areas in the cell were evaluated, as the distribution of organelles may differ depending
1134 on the cell area.

1135 **Structural analysis.** A model of the ARF1 crystal structure (2J59) retrieved from the Protein Data
1136 Bank (PDB) and visualised in UCSF Chimera 1.15. Only Chain A was displayed and R99C was
1137 highlighted by displaying the atom model.

1138 **Purification of ARF1, ARF1R99C and ARF1Q71L.** For bacterial protein expression, soluble
1139 human ARF1 wild-type and mutants lacking its N-terminal 17 amino acids and human ARFGAP1
1140 domain (1-136) were cloned into modified pET16 vector with N-terminal His₆-MBP-SUMO tag.
1141 *E. coli* BL21 Rosetta cells were grown at 37°C in lysogenic broth medium until the culture reached
1142 an OD₆₀₀ of 0.4-0.5 and protein production was induced at 18°C with 0.4 mM isopropyl-β-
1143 thiogalactopyranoside for 16 hours. Harvested *E. coli* cells were resuspended in lysis buffer (20
1144 mM HEPES pH 7.5, 400 mM NaCl, 30 mM imidazole, 10% glycerol and 1 mM β-
1145 mercaptoethanol) and lysed by sonication. Recombinant cell debris was removed by centrifugation
1146 and recombinant hARF1 proteins were purified over nickel-nitriloacetic acid (Ni-NTA) affinity
1147 chromatography and the His₆-MBP-SUMO tag was subsequently removed by addition of SENP2
1148 protease at 4°C, followed by overnight dialysis against 20 mM HEPES pH 7.5, 250 mM NaCl and
1149 2 mM β-mercaptoethanol. The proteins were further purified and separated from His₆-MBP-
1150 SUMO tag and protease by a HiLoad 16/600 Superdex 75 size exclusion chromatography column
1151 (Cytiva) in 20 mM HEPES pH7.5, 250 mM NaCl, 1 mM TCEP. Purified hARF1 were pooled,
1152 aliquoted and flash frozen in liquid nitrogen before stored at -80°C.

1153 **Thermal shift assay.** The thermal stability of different hARF1 proteins in presence and absence
1154 of GTP was analysed by fluorescence thermal shift assays. 75 μM protein were incubated in 25
1155 mM HEPES pH 7.5, 100 mM NaCl, 5 mM MgCl₂, 1 mM TCEP with or without 5 mM GTP. The
1156 fluorescence signal was detected after addition of SYPRO orange (final concentration 5x, Invitro-
1157 gen) using gradient from 15°C to 95°C with 0.5°C/30s and one scan each 0.5°C in a real time
1158 thermal cycler (QuantStudio 3, Thermo Fisher Scientific). The deflection point of the curve and
1159 first derivative was calculated by Prism 9 (GraphPad).

1160 **Autophagy Reporter Assay.** The autophagosome levels of HEK 293T cells stably expressing
1161 LC3B-GFP were assessed as previously⁶². HEK293T cells were transfected with Tag-RFP ARF1
1162 WT, Tag-RFP ARF1 R99C or empty vector using PEI. 6 hours after transfection the medium was
1163 changed to reduce effects of transfection reagents on the cells. For samples that were treated with
1164 Bafilomycin A1, Bafilomycin A1 at a concentration of 625 μ M was added to the medium. 24 h
1165 after treatment, the samples were detached and transferred to 96-well V-bottom plates. Treatment
1166 with 0.05% saponin in PBS and two subsequent washes with PBS were used to remove cytosolic
1167 LC3B-GFP. Fluorescence intensity of membrane-bound LC3B-GFP was measured using a
1168 Beckman-Coulter CytoFLEX with attached high-throughput sampler and set above 1000 to allow
1169 for detection of shifts in autophagosome levels in both directions (more or less autophagosomes).
1170 Intact single cells were gated using SSC-A / FSC-A and FSC-A / FSC-H respectively. Raw
1171 fluorescence-activated cell sorting (FACS) data were analysed using FlowJo 10. Median
1172 fluorescence intensity shifts of all samples were calculated by subtracting the LC3B-GFP-MFI of
1173 vector-treated samples from the ARF1 WT and ARF1 R99C samples.

1174 **Quantification and statistical analysis.** Statistical analyses were performed using GraphPad
1175 PRISM 8. P-values were determined using a two-tailed Student's t test with Welch's correction or
1176 One-way ANOVA for multiple comparisons (Mann-Whitney test). Statistics on qPCRs over
1177 multiple values (Fig. 3f and Extended Data Fig. 3c-f) were performed using Two-Way ANOVA.
1178 Unless otherwise stated, data are shown as the mean of at least three biological replicates \pm SEM.
1179 Significant differences are indicated as: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$. Not significant
1180 differences are not indicated. Specific statistical parameters are specified in the figure legends.

1181

1182 **Extended Data Figure legends**

1183 **Extended Data Figure 1: a**, Conservation of the amino acids in ARF1 (blue, conserved,; white,
1184 not conserved), with R99 highlighted in red as analysed by Consurf . **b**, Pedigrees of the four
1185 patients ascertained with a substitution at R99 of ARF1.

1186

1187 **Extended Data Figure 2: Expression of ARF1 WT and ARF1 R99C. a**, FLAG-tagged ARF1
1188 WT, R99C, Q71L or T31N were transiently expressed in 293-Dual-hSTING-R232 reporter cells.
1189 Representative immunoblots of whole cell lysates (WCLs) showing the corresponding expression
1190 of STING and GAPDH, stained with anti-STING and anti-GAPDH. **b**, Exemplary immunoblot of
1191 WCLs of HEK293T cells transiently expressing FLAG-tagged ARF1 WT or R99C and co-
1192 expressing STING-FLAG (bottom) or empty vector (top). Blots were stained with anti-FLAG,
1193 anti-STING and anti-GAPDH. **c**, Impact of ARF1 WT or R99C expression on ISG induction in
1194 primary human normal lung fibroblasts (NHLF) as assessed by qPCR of Mx1 mRNA 72 h post
1195 transduction. IFN- β (1000 U/mL, 16 h) and cGAMP (10 μ g/ml, 16 h) served as positive controls.
1196 Bars represent mean of $n = 3 \pm$ SEM (biological replicates).

1197

1198 **Extended Data Figure 3: Depletion of mtDNA reduces ISG induction in the presence of**
1199 **ARF1 R99C. a**, Impact of transient transfection of FLAG-tagged ARF1 WT or R99C on ISRE
1200 promoter activity in 293-Dual-hSTING-R232 cells either mock treated or treated with G140 (2.5
1201 μ g/ml, 32 h). SEAP activity was quantified 32 h post transfection and normalised to cell viability.
1202 Bars represent mean of $n = 3 \pm$ SEM (biological replicates). Lower panel: Corresponding
1203 immunoblots of WCLs stained by anti-FLAG, anti-STING and anti-GAPDH. **b**, mtDNA depletion
1204 in U2OS and U2OS-STING cells assessed by qPCR for the mitochondrial gene MT-COXII and
1205 the nuclear gene GAPDH. mtDNA depletion was induced by treating the cells with 100 μ M 2',3'

1206 dideoxycytidine (ddC) for seven to fourteen days. Bars represent mean of $n = 3 \pm$ SEM (biological
1207 replicates). **c**, Exemplary immunoblot of WCLs of U2OS and U2OS-STING cells left untreated
1208 (NT) or treated with 100 μ M ddC for seven to fourteen days and subsequently stimulated with HT-
1209 DNA (2 μ g/mL, 4 h) or treated with lipofectamine (Lipo) only. Blots were stained with anti-pIRF3,
1210 anti-IRF3, anti-pSTING, anti-STING and anti-cofilin. **d-f**, Impact of ARF1 WT, R99C or empty
1211 vector (EV) expression on ISG induction in U2OS and U2OS-STING cells treated with 100 μ M
1212 ddC for seven to fourteen days or left untreated (NT). mRNA levels of Mx1, IFNB1 and RSAD2
1213 were assessed by qPCR 24 h post transfection. Bars represent mean of $n = 3 \pm$ SEM (biological
1214 replicates). **g**, Impact of ARF1 WT and ARF1 R99C on autophagosome levels. HEK293T cells
1215 stably expressing eGFP-LC3b were transfected with TagRFP-ARF1 WT, TagRFP-ARF1 R99C or
1216 empty vector control. Shifts in autophagosome levels were assessed using flow cytometry. $n = 4$
1217 \pm SEM (biological replicates). **h**, Impact of ARF1 WT and ARF1 R99C on autophagosome levels
1218 in the presence and absence of Bafilomycin A1. HEK293T cells stably expressing eGFP-LC3b
1219 were transfected with TagRFP-ARF1 WT, TagRFP-ARF1 R99C or empty vector control. Shifts
1220 in autophagosome levels were assessed using flow cytometry. $n = 4 \pm$ SEM (biological replicates)
1221 **i**, qPCR of mtDNA (MT-D-Loop) in the cytosolic fraction of ARF1 WT, R99C, Q71L and vector
1222 transfected HEK293T ATG5 KO relative to total normalized cellular mtDNA (mtDNA/nuclear
1223 DNA) using the $\Delta\Delta$ CT method. $n = 4 \pm$ SEM. **j**, Analysis of the mitochondrial footprint from the
1224 images shown in (**k**) using the MiNA plugin (StuartLab) for ImageJ (Fiji). Lines represent mean
1225 of $n = 51-62 \pm$ SEM (individual cells). **k**, Exemplary live cell confocal laser scanning microscopy
1226 images of HeLa cells expressing TagRFP-tagged ARF1 WT, R99C or vector control. Cells were
1227 treated with Mitotracker (1 μ M) for 30 min at 37°C. Nuclei, Hoechst 33342 (blue). Scale bar, 10
1228 μ m, **l**, Exemplary immunoblot of WCLs of HEK293T cells transiently expressing ARF1 WT,
1229 R99C or vector control. Blots were stained with anti-pDRP1, anti-DRP1, anti-FLAG and anti-

1230 GAPDH. Quantification of the band intensities for pDRP1 normalized to the band intensities of
1231 DRP1. Bars represent mean of $n = 8 \pm$ SEM (biological replicates).

1232

1233 **Extended Data Figure 4: Characterisation of stability and dimerization of ARF1 WT and**

1234 **R99C. a**, Coomassie stained SDS-PAGE gel of purified recombinant human ARF1 WT, Q71L

1235 and R99C proteins lacking its N-terminal 17 amino acids. **b**, Thermal shift assay of ARF1 WT,

1236 Q71L and R99C. Respective inflection temperatures are: ARF1 WT 58.3 °C; ARF1 R99C 44.4

1237 °C; ARF1 Q71L 56.8 °C. Data are representative of two biological replicates. **c**,

1238 Immunoprecipitation (IP) of FLAG-tagged ARF1 WT and R99C by anti-FLAG-beads. HEK293T

1239 cells were transfected with empty vector, FLAG-tagged ARF1 WT or R99C (FLAG), or TagRFP-

1240 tagged ARF1 WT or R99C (TR), or with FLAG-tagged ARF1 WT and TagRFP-tagged ARF1 WT

1241 or FLAG-tagged ARF1 R99C and TagRFP-tagged ARF1 R99C (FLAG+TR). 24 h post

1242 transfection, cells were harvested and anti-FLAG IP was performed. Blots were stained with anti-

1243 RFP (TR), anti-ARF1 and anti-FLAG. **d-e**, IP of FLAG-tagged ARF1 WT and R99C by anti-

1244 FLAG-beads, from cell lysates of HEK293T cultivated in SILAC light medium or heavy medium

1245 for five passages, then transfected with empty vector, FLAG-tagged ARF1 WT or ARF1 R99C,

1246 harvested and lysed 24 h post transfection. After electrophoresis, in **(d)** western blot was performed

1247 and stained with anti-FLAG and anti-GAPDH, in **(e)** gel was stained with SDS-Gels silver

1248 staining. HC: heavy chain, LC: light chain.

1249

1250 **Extended Data Figure 5: ARF1 mediated ERGIC morphology and retrograde transport**

1251 **from the ERGIC/Golgi to the ER. a**, FLAG-tagged ARF1 WT and R99C were transiently

1252 expressed in HEK293T cells co-expressing STING-FLAG, ISRE-promoter controlled Firefly

1253 luciferase and GAPDH-promoter controlled Renilla luciferase. Representative immunoblots of
1254 WCLs showing the corresponding expression of ARF1 WT, R99C, STING and GAPDH, stained
1255 with anti-FLAG and anti-GAPDH. **b**, Exemplary immunoblot of WCLs for Fig. 5c. Blots were
1256 stained with anti-FLAG and anti-GAPDH. **c**, Exemplary confocal laser scanning microscopy
1257 images of HeLa cells expressing FLAG-tagged ARF1 WT, R99C, Q71L or T31N, corresponding
1258 to Fig. 5g. Cells were stained 24 h post transfection with anti-FLAG (red) and anti-ERGIC-53
1259 (grey). Nuclei, DAPI (blue). Scale bar, 10 μ m. **d**, Exemplary confocal laser scanning microscopy
1260 images of HeLa cells expressing VSVG-ts045-KDEL-eGFP (green) and indicated FLAG-tagged
1261 ARF1 mutants, corresponding to Fig. 5h. Cells were incubated at 37°C for 24 h and the different
1262 temperature shifts (37°C/32°C/40°C) as indicated. Staining with anti-FLAG (red) and anti-GM130
1263 (grey). Nuclei, DAPI (blue). Scale bar, 10 μ m.

1264

1265 **Extended Data Figure 6: ARF1 R99C has increased localisation at the cis- and trans-Golgi.**

1266 **a**, Exemplary confocal laser scanning microscopy images of STING-eGFP (green) and indicated
1267 FLAG-tagged ARF1 mutants in HeLa cells. Cells were stained 24 h post transfection with anti-
1268 FLAG (red) and anti-ERGIC-53 (grey). Nuclei, DAPI (blue). Scale bar, 10 μ m, **b**, Quantification
1269 of the co-localisation of ARF1 and ERGIC-53 and **c**, STING and ERGIC-53 from the images
1270 shown in **(a)** using Pearson's correlation coefficient. Lines represent mean of $n = 15-31 \pm$ SEM
1271 (individual cells). **d**, Exemplary confocal laser scanning microscopy images of STING-eGFP
1272 (green) and indicated FLAG-tagged ARF1 mutants in HeLa cells. Cells were stained 24 h post
1273 transfection with anti-FLAG (red) and anti-TGN46 (grey). Nuclei, DAPI (blue). Scale bar, 10 μ m.
1274 **e**, Quantification of the co-localisation of ARF1 and TGN46 and **f**, STING and TGN46 from the
1275 images shown in **(d)** using Pearson's correlation coefficient. Lines represent mean of $n = 11-18 \pm$
1276 SEM (individual cells). **g**, Exemplary STED super-resolution microscopy images of NHLF cells

1277 transduced with lentiviruses expressing indicated ARF1 constructs or empty vector. 48 h post
1278 transduction the cells were stained with anti-STING (green), anti-FLAG (not shown) and anti-
1279 GM130 (red). Only FLAG-staining positive cells are displayed. Scale bar, 5 μ m.

1280

1281 **Extended Data Figure 7: Model summarizing the involvement of ARF1 in cGAS-STING**
1282 **signal triggering and termination.**

1283

1284 **Supplementary table 1: Molecular data relating to ARF1***

1285

Patient	Nucleotide	Amino acid	Inheritance	gnomAD	SIFT / Polyphen2 / MutationTaster
1	c.295C>T	p.(Arg99Cys)	De novo	0	Deleterious / Probably damaging / Deleterious
3	c.295C>T	p.(Arg99Cys)	De novo	0	Deleterious / Probably damaging / Deleterious
4	c.295C>T	p.(Arg99Cys)	Mother wild-type; paternal DNA not available	0	Deleterious / Probably damaging / Deleterious
2	c.296G>A	p.(Arg99His)	De novo	0	Deleterious / Probably damaging / Deleterious

1286

1287 **Supplementary table 2:** SILAC data

1288

1289 **Supplementary table 3:** PantherDB GO term Analysis

1290

1291 **Supplementary information**

1292 Please contact the corresponding authors to request access to this information.

1293

Figure 1

Hirschenberger et al.




Figure 2

Hirschenberger et al.




Figure 3

Hirschenberger et al.




Figure 4

Hirschenberger et al.




Figure 5

Hirschenberger et al.




Figure 6

Hirschenberger et al.

